[
  {
    "start": "0",
    "end": "377000"
  },
  {
    "text": " The following content is\nprovided under a Creative Commons license. Your support will help\nMIT OpenCourseWare",
    "start": "0",
    "end": "6029"
  },
  {
    "text": "continue to offer high-quality\neducational resources for free. To make a donation or to\nview additional materials",
    "start": "6030",
    "end": "12660"
  },
  {
    "text": "from hundreds of MIT courses,\nvisit MIT OpenCourseWare at ocw.mit.edu.",
    "start": "12660",
    "end": "17992"
  },
  {
    "text": " WILLIAM BONVILLIAN:\nSo I try to do",
    "start": "17992",
    "end": "23930"
  },
  {
    "text": "this at least every other class\nso we remember the context. But class 1, as\nyou remember, was",
    "start": "23930",
    "end": "30140"
  },
  {
    "text": "all about the\neconomic growth theory and the economic growth\ncontext for innovation policy.",
    "start": "30140",
    "end": "38240"
  },
  {
    "text": "And we did growth economics\nand how it broke away",
    "start": "38240",
    "end": "43310"
  },
  {
    "text": "from classical economics\naround developing a new theory of growth. So Solow argued that there's\ntechnological related",
    "start": "43310",
    "end": "51859"
  },
  {
    "text": "innovation. And we concluded that was a\nkey direct innovation factor.",
    "start": "51860",
    "end": "59700"
  },
  {
    "text": "So we could loosely,\nalthough in accurately, translate that concept as\nsaying, you've got to do R&D.",
    "start": "59700",
    "end": "68030"
  },
  {
    "text": "And then we read Romer. And Romer argued that\nbehind that R&D system is human capital\nengaged in research.",
    "start": "68030",
    "end": "74509"
  },
  {
    "text": "That's another foundational\ndirect innovation factor. You can't build an\ninnovation system",
    "start": "74510",
    "end": "79729"
  },
  {
    "text": "without these two\nelements arguably. So it's the R&D and\nthe talent behind it. Those give us two\ndirect factors.",
    "start": "79730",
    "end": "86330"
  },
  {
    "text": "Then in class 2, we talked\nabout the indirect elements in this larger ecosystem.",
    "start": "86330",
    "end": "93410"
  },
  {
    "text": "And government controls some. Private sector controls more. But that gives us an idea\nof looking at innovation",
    "start": "93410",
    "end": "100579"
  },
  {
    "text": "as a system, which Richard\nNelson contributed to. And then within that system,\nyou look at the strength",
    "start": "100580",
    "end": "107210"
  },
  {
    "text": "of the innovation actors. And you can begin to think of\nyour innovation organization as a third direct\ninnovation factor.",
    "start": "107210",
    "end": "115430"
  },
  {
    "text": "And that leads us\ninto the whole problem of how do you cross\nthe valley of death if you've got a\ndisconnected model.",
    "start": "115430",
    "end": "122860"
  },
  {
    "text": "Classes 3 and 4 were case\nstudies on manufacturing. So we took a deep dive\ninto a very current set",
    "start": "122860",
    "end": "129310"
  },
  {
    "text": "of practical, ongoing problems\nto try and think about some of those innovation\norganization lessons",
    "start": "129310",
    "end": "135700"
  },
  {
    "text": "in a manufacturing context. Class 5 was explicitly about\ninnovation organization.",
    "start": "135700",
    "end": "144130"
  },
  {
    "text": "And we looked at David\n[? Hart's ?] analysis of the ideology behind\nlooking at innovation",
    "start": "144130",
    "end": "155239"
  },
  {
    "text": "in the political system\nand the conservative, the associationalist, which\nis the public private,",
    "start": "155240",
    "end": "161080"
  },
  {
    "text": "the national security models. All those issues are\nstill very much with us.",
    "start": "161080",
    "end": "168870"
  },
  {
    "text": "And in that class,\nwe also talked about Donald Stokes' work\nwhere he critiqued the split",
    "start": "168870",
    "end": "177770"
  },
  {
    "text": "in the US innovation\norganizational system between front-end\ninnovation, the R",
    "start": "177770",
    "end": "183379"
  },
  {
    "text": "side and the later stages. So when we organize to do,\nessentially, a research",
    "start": "183380",
    "end": "193190"
  },
  {
    "text": "model at the end of World War\nII under that pipeline model that Vannevar Bush\ngave us, we missed",
    "start": "193190",
    "end": "201659"
  },
  {
    "text": "issues that subsequently\nrose in the economy and became really deep\nsources of problems",
    "start": "201660",
    "end": "206670"
  },
  {
    "text": "about the connections to the\nfall of one implementation back into the innovation\nsystem stages.",
    "start": "206670",
    "end": "213240"
  },
  {
    "text": "Class 6 was about crossing\nthis valley of death. How do you build\nthe bridging models",
    "start": "213240",
    "end": "219030"
  },
  {
    "text": "that get you from a\npipeline innovation model across to the later stages. That's not easy in our system.",
    "start": "219030",
    "end": "226660"
  },
  {
    "text": "And then we also\ntalked about the fact that we run two parallel\nsystems in the US.",
    "start": "226660",
    "end": "232170"
  },
  {
    "text": "So Vernon Ruttan's book, Is War\nNecessary for Economic Growth, introduced us into the whole\nDefense Innovation system,",
    "start": "232170",
    "end": "239470"
  },
  {
    "text": "which is not disconnected. That's a pretty connected model. And the Defense\nDepartment will typically",
    "start": "239470",
    "end": "245610"
  },
  {
    "text": "perform the research,\nthe development. It will do the demonstration. It will do the test bed.",
    "start": "245610",
    "end": "252480"
  },
  {
    "text": "It will move to the\nadvanced prototypes and will often provide\nan initial market for emerging technologies.",
    "start": "252480",
    "end": "258720"
  },
  {
    "text": "That's a very different\norganizational system as we discussed from what the\ncivilian agencies are up to.",
    "start": "258720",
    "end": "265650"
  },
  {
    "text": "Class 7 was innovation at\nthe face-to-face level. That's our whole\ngreat group's theory. So if innovation has to\ndo with institutions,",
    "start": "265650",
    "end": "275813"
  },
  {
    "text": "which it certainly does--\nhow are those institutions organized and how\ndo they connect and how are the handoffs\nbetween the actors?",
    "start": "275813",
    "end": "282210"
  },
  {
    "text": "But in the end, people own\ninnovation, not institutions. It's very face to face.",
    "start": "282210",
    "end": "288888"
  },
  {
    "text": "And then in the\ngreat groups classes, you remember well\nwe talked about some of the rule sets\nthat tend to guide",
    "start": "288888",
    "end": "297570"
  },
  {
    "text": "the way in which great\ngroup-based innovation operates.",
    "start": "297570",
    "end": "302889"
  },
  {
    "text": "And again, that drives us\nback to this third innovation factor-- what does innovation look\nlike an organizational point",
    "start": "302890",
    "end": "309410"
  },
  {
    "text": "of view, from a\nsystems point of view, from an actor's point\nof view, but also,",
    "start": "309410",
    "end": "315710"
  },
  {
    "text": "how does innovation look\nat the face-to-face level. And then in class 8,\nwe talked about DARPA,",
    "start": "315710",
    "end": "321503"
  },
  {
    "text": "which is an institution\nthat actually attempts to do both on a good day. It will support\nthat connectedness",
    "start": "321503",
    "end": "328550"
  },
  {
    "text": "of innovation institutions\nbeing connected",
    "start": "328550",
    "end": "334159"
  },
  {
    "text": "using that defense model. But it will also attempt\nto build great groups.",
    "start": "334160",
    "end": "343280"
  },
  {
    "text": "And we talked about JCR\nLicklider and the evolution of the IT revolution,\na lot of the origins",
    "start": "343280",
    "end": "349260"
  },
  {
    "text": "of which came out of\nDARPA-supported research as an example of that. So now, we're going to do some\nmore case studies in today's",
    "start": "349260",
    "end": "360570"
  },
  {
    "text": "class really looking at the\nlife science innovation system and how does that function.",
    "start": "360570",
    "end": "365820"
  },
  {
    "text": "And we're going to take\na lot of the lessons that we've been learning\nand try and fit them into analyzing this\nreally important piece",
    "start": "365820",
    "end": "374349"
  },
  {
    "text": "into this territory. Let me give you a quick\nNIH historical backdrop.",
    "start": "374350",
    "end": "381690"
  },
  {
    "start": "377000",
    "end": "555000"
  },
  {
    "text": "Remember the pre World War II\nand the World War II context? NIH just stood up as a\nVannevar Bush basic research",
    "start": "381690",
    "end": "389970"
  },
  {
    "text": "organization. So Franklin Roosevelt\nin Vannevar Bush see what happens\nin World War II.",
    "start": "389970",
    "end": "397080"
  },
  {
    "text": "They see the development of\nantibiotics led by penicillin.",
    "start": "397080",
    "end": "402120"
  },
  {
    "text": "And the effects are\nbreathtaking, absolutely breathtaking. So suddenly, we fight a war.",
    "start": "402120",
    "end": "407370"
  },
  {
    "text": "And you probably\nwon't die of disease. You'll actually die of\nbattlefield injuries, which",
    "start": "407370",
    "end": "412440"
  },
  {
    "text": "has never happened before. And that immediately\nhas an effect.",
    "start": "412440",
    "end": "418027"
  },
  {
    "text": "It removes pneumonia\nfrom the number 1 cause of death in the\nUnited States conceivably further down the list.",
    "start": "418027",
    "end": "423750"
  },
  {
    "text": "It's very dramatic. Bush and Roosevelt see\nthis and understand how powerful that model is.",
    "start": "423750",
    "end": "429870"
  },
  {
    "text": "And so one of the theories\nin The Endless Frontier that Vannevar Bush puts\nout, as you remember,",
    "start": "429870",
    "end": "435497"
  },
  {
    "text": "is that there's going to\nbe a war against disease. And they've just seen\nwhat this model is. So they want to do it.",
    "start": "435497",
    "end": "443020"
  },
  {
    "text": "Now, Truman, as you remember,\nvetoes the one agency, One Tent National\nScience Foundation role.",
    "start": "443020",
    "end": "451410"
  },
  {
    "text": "So he vetoes that in\nlike, is it '47 or '49? And that leaves a void.",
    "start": "451410",
    "end": "459510"
  },
  {
    "text": "So voids tend to get filled. So this little\nresearch outfit that's part of the Public Health\nService, the National",
    "start": "459510",
    "end": "467680"
  },
  {
    "text": "Institutes of Health becomes\nthe National Institutes and really starts scaling up.",
    "start": "467680",
    "end": "472750"
  },
  {
    "text": "So follows a Vannevar\nBush basic research model.",
    "start": "472750",
    "end": "478390"
  },
  {
    "text": "But it evolves in this gap\nof organizational leadership",
    "start": "478390",
    "end": "484990"
  },
  {
    "text": "in a way and fills that void. And then over time,\ndisease groups",
    "start": "484990",
    "end": "493670"
  },
  {
    "text": "tend to be very\nactive politically. If you have a disease or if\na loved one has a disease,",
    "start": "493670",
    "end": "499310"
  },
  {
    "text": "you tend to be very active\nin the disease group. And these disease groups push\ntheir disease in Congress.",
    "start": "499310",
    "end": "508070"
  },
  {
    "text": "And Congress keeps adding\ninstitutes and centers onto the model.",
    "start": "508070",
    "end": "513380"
  },
  {
    "text": "When it reaches an\nunmanageable number of 27, finally, Congress actually\ntries to restrain itself.",
    "start": "513380",
    "end": "521015"
  },
  {
    "text": " But it creates an organizational\nmodel that's problematic.",
    "start": "521015",
    "end": "528820"
  },
  {
    "text": "Now, another feature here is-- here's a line from Tony Fauci. It's one of the-- He's the director of\nNIAID, quite famous.",
    "start": "528820",
    "end": "537220"
  },
  {
    "text": "NIAID was one of the\nleaders in getting on all kinds of infectious\ndiseases, including AIDS.",
    "start": "537220",
    "end": "544329"
  },
  {
    "text": "But Tony Fauci writes\nin 2003, \"the path to product development has not\nbeen a part of NIAID's research",
    "start": "544330",
    "end": "552610"
  },
  {
    "text": "strategy.\" In other words, that's\nnot on the table.",
    "start": "552610",
    "end": "559459"
  },
  {
    "start": "555000",
    "end": "644000"
  },
  {
    "text": "They're worried about their\nbasic research results. So what did NIH--",
    "start": "559460",
    "end": "565610"
  },
  {
    "text": "and arguably, the biotech\nmodel that is spawned from it-- what did they get right?",
    "start": "565610",
    "end": "570769"
  },
  {
    "text": "And they get a lot\nof things right. It's an amazing system. It's a remarkable\nstory of success. So even though we're going\nto be critical today,",
    "start": "570770",
    "end": "578330"
  },
  {
    "text": "it is an amazing success story. NIH trained everybody.",
    "start": "578330",
    "end": "583440"
  },
  {
    "text": "It created this huge education\nsystem that put a lot of talent",
    "start": "583440",
    "end": "590000"
  },
  {
    "text": "on the task in Romer's terms. This knowledge base helped spawn\na remarkable entrepreneurial",
    "start": "590000",
    "end": "598670"
  },
  {
    "text": "biotech startup model. And we talked about Genentech\nduring our great groups class.",
    "start": "598670",
    "end": "604490"
  },
  {
    "text": "That's the first. But that's a very good example\nof what then flourished.",
    "start": "604490",
    "end": "610279"
  },
  {
    "text": "And Boyer and Swanson\nwere the founders. Boyer comes out of\nthat NIH-funded system.",
    "start": "610280",
    "end": "620550"
  },
  {
    "text": "Biotechs have been able to\nget venture capital support even though they have a 10 to\n15 year stand-up model, which",
    "start": "620550",
    "end": "629717"
  },
  {
    "text": "is a remarkable accomplishment. No other sector is able to\nget venture capital money unless they're no\nmore than a couple",
    "start": "629718",
    "end": "635300"
  },
  {
    "text": "of years out of production. Biotechs have been able to break\nthat and get long-term support",
    "start": "635300",
    "end": "643250"
  },
  {
    "text": "for R&D. And the key to this has\nbeen the value of IP.",
    "start": "643250",
    "end": "649960"
  },
  {
    "start": "644000",
    "end": "886000"
  },
  {
    "text": "So there is a working monopoly\nmodel in the biotech sector. So if you're first\nto patent a new drug,",
    "start": "649960",
    "end": "661459"
  },
  {
    "text": "you are given a monopoly\nrent for a 20-year time period minus the\ntime it gets you",
    "start": "661460",
    "end": "667790"
  },
  {
    "text": "to get through clinical\ntrials with NIH, which can be seven years. So it's a 13-year\nrun where you're",
    "start": "667790",
    "end": "673910"
  },
  {
    "text": "assured of monopoly rents. And unlike the hard\ntechnology sector,",
    "start": "673910",
    "end": "679130"
  },
  {
    "text": "it's harder to\nstand up, in effect, copy-cat fixes, copy-cat drugs.",
    "start": "679130",
    "end": "688100"
  },
  {
    "text": "So you really do get a\nsignificant run typically if you're first\nto patent and you",
    "start": "688100",
    "end": "693830"
  },
  {
    "text": "get ahead first through\nthe clinical trial process. So that's been the\nenabler that allows",
    "start": "693830",
    "end": "702620"
  },
  {
    "text": "this financing system to work. The other key feature\nis FDA's approval. So FDA gives you--",
    "start": "702620",
    "end": "708880"
  },
  {
    "text": "in stage 1, stage 2,\nstage 3 clinical trials, if you're developing\na cancer drug,",
    "start": "708880",
    "end": "714610"
  },
  {
    "text": "you know exactly\nwhat your chances are on getting through\nthe from stage 1 to stage 2 and stage 2 to\nstage 3 and from stage 3",
    "start": "714610",
    "end": "724000"
  },
  {
    "text": "to final drug approval. You know just what\nyour chances are. So that enables\nventure capitalists",
    "start": "724000",
    "end": "730000"
  },
  {
    "text": "to tee off their\nstages of financing to your success in the\nclinical trials process.",
    "start": "730000",
    "end": "735940"
  },
  {
    "text": "There is no benchmarking system\nlike this in any other sector in the economy. It works amazingly well.",
    "start": "735940",
    "end": "742330"
  },
  {
    "text": "And then another big\ndifference between life science and everything else is that,\nif FDA approves your drug,",
    "start": "742330",
    "end": "748900"
  },
  {
    "text": "you are guaranteed a market. In fact, our\nwonderful legal system is such that, if a doctor fails\nto prescribe the medicine which",
    "start": "748900",
    "end": "756910"
  },
  {
    "text": "is fitted to your problem, the\nnext day, the doctor gets sued.",
    "start": "756910",
    "end": "762129"
  },
  {
    "text": "So there's this huge forcing\nmechanism in the system. There's nothing like a\ncertification that guarantees",
    "start": "762130",
    "end": "768542"
  },
  {
    "text": "you a market on the next day. There's nothing like this\nanywhere else in our system. It's a remarkable thing.",
    "start": "768542",
    "end": "774480"
  },
  {
    "text": "And we can start to\nthink about how do you get analogous certification\nprocesses and benchmarking",
    "start": "774480",
    "end": "780699"
  },
  {
    "text": "processes in place\nin more physical science-based technologies. It would be very interesting. We haven't done it.",
    "start": "780700",
    "end": "786770"
  },
  {
    "text": "But there's a lot to be\nlearned from this sector because of the\nsystem it's setup. ",
    "start": "786770",
    "end": "793180"
  },
  {
    "text": "Upstairs-downstairs\nhas historically been a problem, particularly\nin European science, but also in US science, whereas\nthe academic researchers have",
    "start": "793180",
    "end": "800620"
  },
  {
    "text": "disdain for the\ncompany researchers. That has really broken\nup and broken apart",
    "start": "800620",
    "end": "807670"
  },
  {
    "text": "in the life science side. So outstanding\nacademics, think Boyer,",
    "start": "807670",
    "end": "814030"
  },
  {
    "text": "who spent time in a biotech. That's not created as\na sound career path.",
    "start": "814030",
    "end": "820450"
  },
  {
    "text": "Boyer had to break the ground. He got a lot of flak\nfor it at the time. But over time, it's\nbecome accepted",
    "start": "820450",
    "end": "826450"
  },
  {
    "text": "that you can have an academic\ncareer, move to a biotech, move back to an academic career.",
    "start": "826450",
    "end": "831910"
  },
  {
    "text": "That's OK. Obviously, this conflict is used\nthroughout that whole process that had to be dealt with.",
    "start": "831910",
    "end": "837550"
  },
  {
    "text": "But that's an\nacceptable pathway. So the whole\nupstairs-downstairs relationship between the academy and\ncommercial development",
    "start": "837550",
    "end": "844780"
  },
  {
    "text": "has really been broken up. So that's another thing\nthat this sector got right.",
    "start": "844780",
    "end": "852220"
  },
  {
    "text": "NIH also has a huge\namount of money. It's by far the\nlargest R&D agency. It's got over $30\nbillion a year.",
    "start": "852220",
    "end": "858610"
  },
  {
    "text": "Nobody is close.  NSF, by comparison,\nhas $7 billion a year.",
    "start": "858610",
    "end": "865630"
  },
  {
    "text": "The Department of Energy Office\nof Science has $5 billion. DARPA has $3 billion. So this is an order of magnitude\nalmost different from other R&D",
    "start": "865630",
    "end": "875110"
  },
  {
    "text": "agencies. So the political constituencies,\nincluding the disease groups, have built a very\npowerful political base",
    "start": "875110",
    "end": "883240"
  },
  {
    "text": "for sustained funding\nin this sector. Now, that's the good news.",
    "start": "883240",
    "end": "889380"
  },
  {
    "start": "886000",
    "end": "1082000"
  },
  {
    "text": "Here's the problem. We're going to talk about\nthe innovation train wreck that lies ahead here.",
    "start": "889380",
    "end": "894710"
  },
  {
    "text": "So the economic model\nfor biotechs and pharmas really requires\nblockbuster markets.",
    "start": "894710",
    "end": "899980"
  },
  {
    "text": "It's a huge problem. So in other words, third-world\ndiseases, infectious diseases,",
    "start": "899980",
    "end": "906100"
  },
  {
    "text": "small-population diseases,\nit doesn't make sense to pursue those.",
    "start": "906100",
    "end": "912820"
  },
  {
    "text": "To get a drug through the FDA\nclinical process to develop in time before, during, and\nduring the clinical trial",
    "start": "912820",
    "end": "920110"
  },
  {
    "text": "approval process itself, that's\naround a $1.4-billion-or-more",
    "start": "920110",
    "end": "925860"
  },
  {
    "text": "proposition. So unless you're selling\nit to a major market, it doesn't make any sense\nto develop the remedy.",
    "start": "925860",
    "end": "934740"
  },
  {
    "text": "So there is a statistic\nthat some cite, which is that 80% of our\nR&D money in life science",
    "start": "934740",
    "end": "947259"
  },
  {
    "text": "is spent on 10% of the diseases. That's a problem.",
    "start": "947260",
    "end": "952949"
  },
  {
    "text": "I don't think the\nnumber is that bad. I think that's exaggerated. But we've got a\nproblem here because of",
    "start": "952950",
    "end": "960260"
  },
  {
    "text": "this blockbuster drug model. Only if you're developing a drug\nthat sells into a major market",
    "start": "960260",
    "end": "966560"
  },
  {
    "text": "opportunity is it going\nto get into the market. So what does that leave behind?",
    "start": "966560",
    "end": "973680"
  },
  {
    "text": "In addition to the\nthings I've mentioned, the precision medicine or\npersonalized drug model",
    "start": "973680",
    "end": "980490"
  },
  {
    "text": "gets left behind. In other words,\nif each one of you is going to have their\nown remedy variant that's",
    "start": "980490",
    "end": "987930"
  },
  {
    "text": "particularly adapted to your\ngenetic structure or metabolism or whatever, what\nare we going to do?",
    "start": "987930",
    "end": "993120"
  },
  {
    "text": "Run a $1.4-billion clinical\ntrial process for you? It's not going to work.",
    "start": "993120",
    "end": "999000"
  },
  {
    "text": "So how do we deal with this? There's a huge looming train\nwreck problem in the system",
    "start": "999000",
    "end": "1006260"
  },
  {
    "text": "because that's where it's going. These are the benefits of\nbeing able to use big data and analytics to develop\npersonalized medicine.",
    "start": "1006260",
    "end": "1012529"
  },
  {
    "text": "But if there's not an economic\nmodel to get it there, it won't happen.",
    "start": "1012530",
    "end": "1018980"
  },
  {
    "text": "The litigation threat makes\ndrug companies risk averse. So we leave a lot\nof promising stuff",
    "start": "1018980",
    "end": "1024559"
  },
  {
    "text": "on the table because\nof that threat. Often, a drug will\ncure, let's say,",
    "start": "1024560",
    "end": "1032329"
  },
  {
    "text": "20%, 30%, maybe 40% of a\ndisease group's problem. But if it kills\nsome people, we'll",
    "start": "1032329",
    "end": "1039050"
  },
  {
    "text": "never go to market because we\ndon't understand the precision medicine, the\npersonalized medicine implications of these things.",
    "start": "1039050",
    "end": "1045650"
  },
  {
    "text": "And until we do, we're\njust leaving a lot of stuff on the shelf that has potential\nvalue because Americans,",
    "start": "1045650",
    "end": "1051890"
  },
  {
    "text": "for good reason, have very low\ntolerance for risk from drugs.",
    "start": "1051890",
    "end": "1057965"
  },
  {
    "text": " The health care spending in\nthe overall system by 2025",
    "start": "1057965",
    "end": "1067530"
  },
  {
    "text": "may account for\n9% of GDP or more. And we'll talk about\nthis in a minute.",
    "start": "1067530",
    "end": "1074040"
  },
  {
    "text": "But we can't afford a health\ncare bill of those dimensions and still have\nother things going",
    "start": "1074040",
    "end": "1079770"
  },
  {
    "text": "on in the society and the\neconomy and the government. ",
    "start": "1079770",
    "end": "1086330"
  },
  {
    "start": "1082000",
    "end": "1463000"
  },
  {
    "text": "This is what we spend money\non in the federal government. ",
    "start": "1086330",
    "end": "1092049"
  },
  {
    "text": "This is what we think\nof as government. So that's like the national\nparks and federal research,",
    "start": "1092050",
    "end": "1098529"
  },
  {
    "text": "transportation, highways. That's this. That's defense.",
    "start": "1098530",
    "end": "1104270"
  },
  {
    "text": "So that's actually about 16%. And that's now about\nmaybe a little below 20%.",
    "start": "1104270",
    "end": "1110350"
  },
  {
    "text": "That's Social Security. That's Medicaid,\nMedicare, and SCHIP,",
    "start": "1110350",
    "end": "1115900"
  },
  {
    "text": "the big health-care-oriented\nentitlement programs. That's other safety\nnet programs, 9%.",
    "start": "1115900",
    "end": "1122559"
  },
  {
    "text": "And then we have interest on\nthe debt, which is actually now over 9%.",
    "start": "1122560",
    "end": "1127850"
  },
  {
    "text": "So as you can see, the\nfederal government is mostly-- we're talking 60% plus\ninterest in the debt--",
    "start": "1127850",
    "end": "1135860"
  },
  {
    "text": "a check-writing kind\nof organization. And that's what we\nthink of as government.",
    "start": "1135860",
    "end": "1141570"
  },
  {
    "text": "And that's what we think\nof as the domestic side of government. So these are pretty\nsmall pieces. Rasheed? AUDIENCE: What year is this for?",
    "start": "1141570",
    "end": "1148470"
  },
  {
    "text": "WILLIAM BONVILLIAN: This is\nprobably about four years old now. But the numbers are slightly\neven more problematic",
    "start": "1148470",
    "end": "1156180"
  },
  {
    "text": "than these. So again, this\ncategory is now 16%. So the numbers are probably\noff by a couple of percent.",
    "start": "1156180",
    "end": "1162910"
  },
  {
    "text": "But it's a problem. And as we'll see\nin a second, these",
    "start": "1162910",
    "end": "1173440"
  },
  {
    "text": "are components of\nfederal spending. So that's health. And that blue line\nis everything else.",
    "start": "1173440",
    "end": "1179150"
  },
  {
    "text": "So you can see where\ntaxpayer dollars are going. ",
    "start": "1179150",
    "end": "1185659"
  },
  {
    "text": "This kind of demonstrates\nthat Social Security is not the real problem. It's really the health\ncare cost related",
    "start": "1185660",
    "end": "1190760"
  },
  {
    "text": "to Medicare and Medicaid\nthat are the problem. ",
    "start": "1190760",
    "end": "1196160"
  },
  {
    "text": "This shows historic\nlevels of taxation.",
    "start": "1196160",
    "end": "1201257"
  },
  {
    "text": "Remember, the United States\nwas founded on a tax revolt. So we're not going to\nhave European-style levels",
    "start": "1201257",
    "end": "1206695"
  },
  {
    "text": "of taxation in\nthe United States. It's just not going to happen. And we start to run into\nreal political trouble",
    "start": "1206695",
    "end": "1212720"
  },
  {
    "text": "once you get a little bit above,\nsay, the 20% level of taxation that's a percentage of GDP.",
    "start": "1212720",
    "end": "1220220"
  },
  {
    "text": "So we're headed way up against\nthat threshold largely because",
    "start": "1220220",
    "end": "1229720"
  },
  {
    "text": "of the demographics and\nthe health care spending, which means that, broken down\nthis way, the percentage of GDP",
    "start": "1229720",
    "end": "1241529"
  },
  {
    "text": "we spend on, what we\nconsider most of government, is just not going\nto be affordable",
    "start": "1241530",
    "end": "1249450"
  },
  {
    "text": "given the acceptable\nlevels, around 19%, 18%,",
    "start": "1249450",
    "end": "1254510"
  },
  {
    "text": "the acceptable tax range\nin our political system. So Max? AUDIENCE: What are [INAUDIBLE]?",
    "start": "1254510",
    "end": "1260550"
  },
  {
    "text": "WILLIAM BONVILLIAN: Expenditures\nby the federal government. What they're spending\nin a given year. What they were actually\noutlaying to meet their costs,",
    "start": "1260550",
    "end": "1267120"
  },
  {
    "text": "to meet their obligations. So these are some of the\nproblems that lie ahead.",
    "start": "1267120",
    "end": "1272235"
  },
  {
    "text": "We got a real fiscal\ntrain wreck because of the cost of this\nhealth care system driven",
    "start": "1272235",
    "end": "1277440"
  },
  {
    "text": "by the demographics. My generation\nattempted to make you",
    "start": "1277440",
    "end": "1283049"
  },
  {
    "text": "spend all of your money on me. That's essentially\nwhat's going on. It's a massive intergenerational\ntransfer of wealth.",
    "start": "1283050",
    "end": "1291670"
  },
  {
    "text": "And you guys need to wake up\nto that because it forgoes opportunities that you have.",
    "start": "1291670",
    "end": "1298600"
  },
  {
    "text": "And at the heart of this\nis a really serious problem with health care expenditures.",
    "start": "1298600",
    "end": "1304380"
  },
  {
    "text": "So let's now get back\ninto our main themes.",
    "start": "1304380",
    "end": "1309650"
  },
  {
    "text": "This was a classic 2003\nreport, what is now called the Academy of Medicine.",
    "start": "1309650",
    "end": "1315440"
  },
  {
    "text": "It used to be called the\nNational Institute of Medicine. It's part of the\nnational academies-- they did on evaluating NIH.",
    "start": "1315440",
    "end": "1325230"
  },
  {
    "text": "And it was a pretty\nstartling criticism. And they looked hard\nat this NIH system.",
    "start": "1325230",
    "end": "1334480"
  },
  {
    "text": "It really began to identify\nsome of the problems. Interestingly, this report drove\nsome interesting congressional",
    "start": "1334480",
    "end": "1343330"
  },
  {
    "text": "reform attempts. Let me see if I can summarize\na few key points here.",
    "start": "1343330",
    "end": "1351145"
  },
  {
    "text": "And Chloe, did\nyou have this one?  You've got it, Martin?",
    "start": "1351145",
    "end": "1356429"
  },
  {
    "text": "OK. All right. So as I said, NIH is more\nlike a feudal barony.",
    "start": "1356430",
    "end": "1366860"
  },
  {
    "text": "It always has a famous director. But they don't have that much\ncontrol over these institutes",
    "start": "1366860",
    "end": "1371870"
  },
  {
    "text": "and centers. There is no\ncentralized budgeting. And the institutes\nand centers battled",
    "start": "1371870",
    "end": "1377840"
  },
  {
    "text": "to protect their percentage\nshare of NIH's total budget.",
    "start": "1377840",
    "end": "1383270"
  },
  {
    "text": "So Harold Varmus, a\nfamous former director of NIH, who later came back\nin the Obama administration",
    "start": "1383270",
    "end": "1389870"
  },
  {
    "text": "as head of the National Cancer\nInstitute, he said, in 2001, \"NIH would be more efficient\nand more manageable",
    "start": "1389870",
    "end": "1397960"
  },
  {
    "text": "if a far smaller number\nof larger institutes existed organized around\nbroad science areas.\"",
    "start": "1397960",
    "end": "1407080"
  },
  {
    "text": "Less institutes, organized\naround science areas is his twin points here.",
    "start": "1407080",
    "end": "1413328"
  },
  {
    "text": "And there's a lot to\nbe said for that case. Instead, as we\ndiscussed, the institutes got set up essentially at\nthe behest of disease groups",
    "start": "1413328",
    "end": "1419710"
  },
  {
    "text": "to solve their disease problem. It turns out there\nisn't a separate pathway",
    "start": "1419710",
    "end": "1426380"
  },
  {
    "text": "for each disease. It turns out there's a\nlot of common pathways across a lot of diseases.",
    "start": "1426380",
    "end": "1432090"
  },
  {
    "text": "And we don't have a very\ngood mechanism in NIH for getting groups of\ninstitutes to collaborate",
    "start": "1432090",
    "end": "1438559"
  },
  {
    "text": "on a cross-cutting\nset of problems. So fundamental\norganizational issue.",
    "start": "1438560",
    "end": "1445160"
  },
  {
    "text": "Now, there is another side\nof this argument, which is, you've got a\nlot of institutes",
    "start": "1445160",
    "end": "1450980"
  },
  {
    "text": "with a lot of freedom\nto do a lot of stuff. Maybe a desegregated\nmodel is not all bad.",
    "start": "1450980",
    "end": "1457910"
  },
  {
    "text": "There's certainly a case\nto be made for that. But overall, there's\na challenge here.",
    "start": "1457910",
    "end": "1463070"
  },
  {
    "start": "1463000",
    "end": "1575000"
  },
  {
    "text": "And NIH's budget doubled\nfrom 1998 to 2003.",
    "start": "1463070",
    "end": "1470120"
  },
  {
    "text": "So there was a federal\nsurplus in its budget",
    "start": "1470120",
    "end": "1476300"
  },
  {
    "text": "during the IT revolution,\nwhich was generating huge amounts of tax revenue. And two US senators saw\nthis emerging surplus.",
    "start": "1476300",
    "end": "1486890"
  },
  {
    "text": "They were on the appropriations\nsubcommittee that handled NIH. And they went to\nthe Senate floor",
    "start": "1486890",
    "end": "1492230"
  },
  {
    "text": "and took a noticeable\npart of that surplus and gave it to NIH.",
    "start": "1492230",
    "end": "1497385"
  },
  {
    "text": "It was a fascinating political\ndevelopment, very shrewd. Arlen Specter of Pennsylvania\nand Tom Harkin of Iowa",
    "start": "1497385",
    "end": "1505909"
  },
  {
    "text": "were chairmen and ranking on\nthe appropriations subcommittee. And they created the doubling.",
    "start": "1505910",
    "end": "1512000"
  },
  {
    "text": "It's a remarkable story. They were able to\ndo it because there was so much excitement\nat that time",
    "start": "1512000",
    "end": "1517909"
  },
  {
    "text": "over the genomics revolution. So we talked about Venter\nand the NIH dueling battle",
    "start": "1517910",
    "end": "1523669"
  },
  {
    "text": "[? Collins ?] over who's going\nto get to the genome first. There was creating\nhuge excitement.",
    "start": "1523670",
    "end": "1528920"
  },
  {
    "text": "It was a sense that\nthis medical research could lead to all kinds of new\nfundamental understandings.",
    "start": "1528920",
    "end": "1534559"
  },
  {
    "text": "Everybody was excited\nabout the idea. And that enabled those two\nsenators to double NIH.",
    "start": "1534560",
    "end": "1540110"
  },
  {
    "text": "No other agency has ever been\nable to do anything like this. The rest were stagnating.",
    "start": "1540110",
    "end": "1546590"
  },
  {
    "text": "But the demographics\nare changing. The patterns of\nillness are changing. We have a threat of biothreats.",
    "start": "1546590",
    "end": "1553820"
  },
  {
    "text": "Is NIH too fragmented to cope\nwith all these challenges? Can it respond quickly enough?",
    "start": "1553820",
    "end": "1559010"
  },
  {
    "text": "These are all issues\nthat the report raises. It wants to avoid\nproliferation of new agencies.",
    "start": "1559010",
    "end": "1565054"
  },
  {
    "text": "And in fact, Congress\ndid that as part of its reform legislation. You can't have a\nnew institute in NIH",
    "start": "1565055",
    "end": "1571130"
  },
  {
    "text": "unless you close\ndown another one. ",
    "start": "1571130",
    "end": "1578410"
  },
  {
    "start": "1575000",
    "end": "2096000"
  },
  {
    "text": "The Institute of Medicine, and\nnow the Academy of Medicine, urged in this report that NIH\nfocus on its capabilities.",
    "start": "1578410",
    "end": "1586570"
  },
  {
    "text": "And it needed to do so because\nit concluded that NIH is not only imperfect, but nobody would\nhave ever designed NIH this way",
    "start": "1586570",
    "end": "1593500"
  },
  {
    "text": "at the outset. And in fact, Elias\nZerhouni once told me in a meeting and\nothers, if only we",
    "start": "1593500",
    "end": "1603279"
  },
  {
    "text": "had thought through the\norganizational model before we doubled.",
    "start": "1603280",
    "end": "1608320"
  },
  {
    "text": "So we doubled first. And then there\nwas a mad scramble to grab the money from\nthe existing institutes.",
    "start": "1608320",
    "end": "1614258"
  },
  {
    "text": "If only they had thought\nabout the organizational model up front. Zerhouni led a great\neffort to try and get",
    "start": "1614258",
    "end": "1622390"
  },
  {
    "text": "cross-cutting research efforts\ngoing across the institute. So he created what he\ncalled the roadmap.",
    "start": "1622390",
    "end": "1628230"
  },
  {
    "text": "But essentially,\nthen Congress later institutionalized that\nas the common fund. Take a little bit of\nmoney from each institute.",
    "start": "1628230",
    "end": "1634360"
  },
  {
    "text": "Create a common fund in the\ncontrol of the director who can then allocate\nit to the highest cross-cutting priorities.",
    "start": "1634360",
    "end": "1641955"
  },
  {
    "text": "So that was a\nsignificant reform. But it's still a very\nmodest amount of money. ",
    "start": "1641955",
    "end": "1649510"
  },
  {
    "text": "NIH needs to pursue\nan ability to go after high-risk,\nhigh-return projects.",
    "start": "1649510",
    "end": "1656360"
  },
  {
    "text": "That reaches a certain stage. And we'll talk about\nthis more later. But peer review is not\ngood at taking risk.",
    "start": "1656360",
    "end": "1665210"
  },
  {
    "text": "If there's a certain\nlevel of competition, if the award rate gets higher\nthan about one out of three,",
    "start": "1665210",
    "end": "1671720"
  },
  {
    "text": "your ability to identify\nbreakthrough opportunities that",
    "start": "1671720",
    "end": "1678080"
  },
  {
    "text": "are feasible gets harder. So it tends to default to--",
    "start": "1678080",
    "end": "1684760"
  },
  {
    "text": "when there's a lot of\ncompetition for an award, the one that the peer\ncommunity is most confident",
    "start": "1684760",
    "end": "1690100"
  },
  {
    "text": "will yield results, albeit\nthey be incremental results. Why take risks on high\nflyers when you've",
    "start": "1690100",
    "end": "1696534"
  },
  {
    "text": "got to get the basics done. And so many people are\nfighting for the money. So this is a huge\nproblem at NIH.",
    "start": "1696535",
    "end": "1701919"
  },
  {
    "text": "How does it take the\nnecessary risks that need to be taken in innovation?",
    "start": "1701920",
    "end": "1708010"
  },
  {
    "text": "So since then, NIH\nhas been working on creating categories\nof higher-risk projects",
    "start": "1708010",
    "end": "1714399"
  },
  {
    "text": "that have a separate\nkind of review process than normal projects. So there are positive\nNIH capabilities.",
    "start": "1714400",
    "end": "1721510"
  },
  {
    "text": "We talked about\nhow decentralized can be an advantage. We talked about many\nsetting R&D priorities.",
    "start": "1721510",
    "end": "1729690"
  },
  {
    "text": "You get a lot of\nsafety nets here. There are benefits to\ninvestigator initiative grants.",
    "start": "1729690",
    "end": "1737200"
  },
  {
    "text": "You don't want to just\nhave large-scale projects. You want bottom-up\nopportunities.",
    "start": "1737200",
    "end": "1742418"
  },
  {
    "text": "The issue for NIH, though,\nis, historically, it's been totally\ndominated by bottom up and has a modest number\nof cross-cutting projects.",
    "start": "1742418",
    "end": "1749140"
  },
  {
    "text": " Peer review in some ways is like\nWinston Churchill's definition",
    "start": "1749140",
    "end": "1755650"
  },
  {
    "text": "of democracy, the worst\npossible system except for all the others.",
    "start": "1755650",
    "end": "1761590"
  },
  {
    "text": "So peer review\nremains competitive. And that's a very important\nfeature to build in.",
    "start": "1761590",
    "end": "1767380"
  },
  {
    "text": "So [? IOM ?] recommended much\nmore centralized management giving more authority\nto the director of NIH,",
    "start": "1767380",
    "end": "1774730"
  },
  {
    "text": "getting the director to\nengage in strategic planning across the institutes so they\ngot on to cross-cutting plans,",
    "start": "1774730",
    "end": "1783190"
  },
  {
    "text": "doing cross-cutting budgets. So this idea of take\n10% of the budget and fund the strategic\nplans, actually, Congress",
    "start": "1783190",
    "end": "1790270"
  },
  {
    "text": "worked on implementing that\nthrough the common fund. Strengthening the\ncontrol of the director",
    "start": "1790270",
    "end": "1797620"
  },
  {
    "text": "over these cross-agency\ninitiatives was key. They also recommended\ncreating a DARPA within NIH",
    "start": "1797620",
    "end": "1804309"
  },
  {
    "text": "to go after the high-risk,\nhigh-reward projects.",
    "start": "1804310",
    "end": "1810550"
  },
  {
    "text": "They wanted improvements in\nNIH as intramural programs. So NIH is also a major\nresearch entity itself.",
    "start": "1810550",
    "end": "1816600"
  },
  {
    "text": "It's not just funding\nuniversities that historically has tended to be somewhat\nweaker than the university",
    "start": "1816600",
    "end": "1822130"
  },
  {
    "text": "research, which is much\nmore competition-based rather than kind of\nentitlement-funding-based. They wanted to strengthen that.",
    "start": "1822130",
    "end": "1829160"
  },
  {
    "text": "There is a desperate\nneed for standardization of data and information\nsystems across these different institutes.",
    "start": "1829160",
    "end": "1835029"
  },
  {
    "text": "Because a lot of these\ndiseases are related, they can learn from each\nother and you can't do",
    "start": "1835030",
    "end": "1841270"
  },
  {
    "text": "cross-cutting data analytics.  So there is a series\nof reform steps here.",
    "start": "1841270",
    "end": "1850090"
  },
  {
    "text": "As going back to some earlier\npoints we've made in the class, NIH is not a connected\norganization.",
    "start": "1850090",
    "end": "1857710"
  },
  {
    "text": "It's an early-stage basic\nresearch organization. It's not connected to\nthe following stages.",
    "start": "1857710",
    "end": "1862900"
  },
  {
    "text": "Now, it has managed to create\na model through biotechs",
    "start": "1862900",
    "end": "1868480"
  },
  {
    "text": "that are venture funded\nthat is able to get across the valley of death if\nyou've got a blockbuster drug.",
    "start": "1868480",
    "end": "1877120"
  },
  {
    "text": "That's pretty creative. Other agencies haven't\ncome up with that.",
    "start": "1877120",
    "end": "1883180"
  },
  {
    "text": "It's not as if NIH was sitting\naround figuring it out. But in effect, it occurred\nand the training of the talent",
    "start": "1883180",
    "end": "1889930"
  },
  {
    "text": "helped it occur through\npeople like Boyer and Swanson. Martine? AUDIENCE: Will we\ndefine blockbuster drugs as the one that makes\na lot of money or one",
    "start": "1889930",
    "end": "1896632"
  },
  {
    "text": "that impacts the disease\nthat a lot of people have? WILLIAM BONVILLIAN: One\nthat makes a lot of money. Right.",
    "start": "1896632",
    "end": "1903190"
  },
  {
    "text": "I mean, in theory, it won't get\nthrough FDA unless it actually solves a problem. ",
    "start": "1903190",
    "end": "1912929"
  },
  {
    "text": "NIH is primarily\nsmall-grant research and lacks the\ncapability to set up",
    "start": "1912930",
    "end": "1918270"
  },
  {
    "text": "initiatives across\nthe stovepipes as we've talked about before. It tends to be\nfairly slow moving.",
    "start": "1918270",
    "end": "1924400"
  },
  {
    "text": "There's a risk in peer\nreview of avoiding high-risk, high-payoff\napproaches. There's limited\nconnections to industry.",
    "start": "1924400",
    "end": "1931380"
  },
  {
    "text": "In other words, that\ntranslational research effect is hard to do it at\nNIH, although Collins,",
    "start": "1931380",
    "end": "1939509"
  },
  {
    "text": "who's the current\ndirector of NIH, has worked on creating a\nspecial translational medicine",
    "start": "1939510",
    "end": "1946170"
  },
  {
    "text": "institute designed\nat that problem. So NIH has been\ntaking steps on this. I think that's a pretty good--",
    "start": "1946170",
    "end": "1951970"
  },
  {
    "text": "I'll give you one more example-- nanotechnology. ",
    "start": "1951970",
    "end": "1958830"
  },
  {
    "text": "The earliest beneficiary\nof nanotechnology was probably the\nsemiconductor sector. But the life science sector,\nthe health research sector",
    "start": "1958830",
    "end": "1965340"
  },
  {
    "text": "was very close. Huge potential,\nopportunity spaces",
    "start": "1965340",
    "end": "1971220"
  },
  {
    "text": "in understanding things\nat the nanoscale here. ",
    "start": "1971220",
    "end": "1978150"
  },
  {
    "text": "Because of the disaggregated\nstructure of NIH,",
    "start": "1978150",
    "end": "1984290"
  },
  {
    "text": "for many, many years after the\nnanotechnology initiative was created, NIH--",
    "start": "1984290",
    "end": "1989630"
  },
  {
    "text": "by far, the largest\nresearch organization-- was only spending a fraction\nof what the National Science",
    "start": "1989630",
    "end": "1995900"
  },
  {
    "text": "Foundation was spending\non nanotechnology, even though the gains for the\nhealth research system",
    "start": "1995900",
    "end": "2003220"
  },
  {
    "text": "were, and clearly\nare, phenomenal. So that's an\nexample of a problem",
    "start": "2003220",
    "end": "2011799"
  },
  {
    "text": "in being able to attack\na whole new approached disease across this very\ndisaggregated model.",
    "start": "2011800",
    "end": "2019060"
  },
  {
    "text": " So that's the IOM\nreport of 2003.",
    "start": "2019060",
    "end": "2026039"
  },
  {
    "text": "We've learned some\nlessons from this. We tried to make some changes. And Congress has actually\nprovided a fair amount",
    "start": "2026040",
    "end": "2031740"
  },
  {
    "text": "of leadership on that in\ncreating the common fund and capping the\nnumber of institutes.",
    "start": "2031740",
    "end": "2037682"
  },
  {
    "text": "Martin, you want to take us\nthrough some questions in this? AUDIENCE: Do you actually want\nto do the Cooke-Deegan one?",
    "start": "2037682",
    "end": "2042928"
  },
  {
    "text": "Because that way I can\njust integrate them. And it might be easier. WILLIAM BONVILLIAN: All right. We can do Deegan\nand do it together. And we don't need to\nspend a lot of time",
    "start": "2042928",
    "end": "2049649"
  },
  {
    "text": "on this because last\nweek's class was on DARPA. So I'm not going to recap this.",
    "start": "2049650",
    "end": "2055830"
  },
  {
    "text": "Robert Cooke-Deegan was\ndeputy when Watson was heading the Genome Project at NIH.",
    "start": "2055830",
    "end": "2062770"
  },
  {
    "text": "So he knows NIH from the inside. He later went on to head\nDuke's Genome Institute.",
    "start": "2062770",
    "end": "2069859"
  },
  {
    "text": "So he's an outstanding\nresearcher. And now, he is teaching\nscience and technology policy",
    "start": "2069860",
    "end": "2079099"
  },
  {
    "text": "at the Washington\nbranch of Arizona State. So he's gone over to the\ndark side of science policy",
    "start": "2079100",
    "end": "2087230"
  },
  {
    "text": "where people like me\ninhabit the world. But he's got real talents,\nunlike me actually,",
    "start": "2087230",
    "end": "2094129"
  },
  {
    "text": "on the technology side. And he wrote this piece\nback in 1996 fairly fresh",
    "start": "2094130",
    "end": "2100580"
  },
  {
    "start": "2096000",
    "end": "2126000"
  },
  {
    "text": "off his own NIH experience,\nDoes NIH Need a DARPA?",
    "start": "2100580",
    "end": "2105890"
  },
  {
    "text": "And I can't tell you how\ncontroversial this was. NIH has always viewed itself\nas better than everybody else.",
    "start": "2105890",
    "end": "2111650"
  },
  {
    "text": "And the fact that\none of their own, the deputy director of\ntheir Genome Project, was telling them there was a\nbetter model out there that",
    "start": "2111650",
    "end": "2118728"
  },
  {
    "text": "they ought to at least\nconsider adopting for part of their operation--\ncertainly, not for all-- was a powerful message.",
    "start": "2118728",
    "end": "2126470"
  },
  {
    "start": "2126000",
    "end": "2261000"
  },
  {
    "text": "And we know the DARPA story. So I'm not going to recap that. Robert Cooke-Deegan underscores\nthat the DARPA model",
    "start": "2126470",
    "end": "2134090"
  },
  {
    "text": "suggests that peer review is\nnot the only way of organizing research.",
    "start": "2134090",
    "end": "2140150"
  },
  {
    "text": "DARPA has far lower transaction\ncosts than NIH does, a lot lower review costs\nper science direction.",
    "start": "2140150",
    "end": "2146657"
  },
  {
    "text": " He introduces this issue of how\nconservative peer review gets",
    "start": "2146657",
    "end": "2154680"
  },
  {
    "text": "when it gets to an\naward rate that's much worse than about one out\nof three applications per grants",
    "start": "2154680",
    "end": "2163510"
  },
  {
    "text": "awarded.  NIH has got a very\nlimited ability",
    "start": "2163510",
    "end": "2168750"
  },
  {
    "text": "to do the grand challenge model,\nto pursue that challenge model.",
    "start": "2168750",
    "end": "2174790"
  },
  {
    "text": "It's got limited ability\nto take high risks and get high rewards. It's got a lower risk\nacceptance capability.",
    "start": "2174790",
    "end": "2182820"
  },
  {
    "text": "Those are DARPA things that NIH\nshould have-- not all of NIH, but certainly some part of\nit-- might adopt, he argues.",
    "start": "2182820",
    "end": "2191190"
  },
  {
    "text": "He cites a lot of examples. ",
    "start": "2191190",
    "end": "2196540"
  },
  {
    "text": "The Human Genome\nInitiative actually originated in the\nDepartment of Energy because the Department of Energy\nunderstood supercomputers.",
    "start": "2196540",
    "end": "2205080"
  },
  {
    "text": "So for the first five years\nof the Genome Project, it was carried by the\nsupercomputer gurus",
    "start": "2205080",
    "end": "2211740"
  },
  {
    "text": "at DOE, because\nthey understood what the potential supercomputing\nwas going to be in figuring out the genetic structure.",
    "start": "2211740",
    "end": "2217920"
  },
  {
    "text": "NIH only picked it up when it\nsaw the promise of the model. NIH had terrible trouble\ncoping with the advances made",
    "start": "2217920",
    "end": "2225720"
  },
  {
    "text": "by Leroy Hood. And we'll talk\nlater about Venter and how do you adapt\nand incorporate",
    "start": "2225720",
    "end": "2232589"
  },
  {
    "text": "a computational model\nin medical research. They're locked into a\nbiology-only drug development",
    "start": "2232590",
    "end": "2238560"
  },
  {
    "text": "model pretty much. It's hard for them to\ndo other territories as we'll talk about when we\nget to the convergence report.",
    "start": "2238560",
    "end": "2245280"
  },
  {
    "text": "So the lessons from\nDARPA for handling",
    "start": "2245280",
    "end": "2250650"
  },
  {
    "text": "multidisciplinary approaches in\nbringing in a group of talent around a problem that comes\nfrom different fields, there's",
    "start": "2250650",
    "end": "2257670"
  },
  {
    "text": "lessons here for NIH. I mean, that's the heart\nof Robert Cooke-Deegan's",
    "start": "2257670",
    "end": "2267240"
  },
  {
    "start": "2261000",
    "end": "3599000"
  },
  {
    "text": "recommendations. And Martine, it's yours.",
    "start": "2267240",
    "end": "2272297"
  },
  {
    "text": "AUDIENCE: So I think you did\na good analysis of the papers. So I won't really\nsummarize too much more.",
    "start": "2272297",
    "end": "2277799"
  },
  {
    "text": "I think we can just go\nstraight into discussion. And so I think a good first\nquestion would be, how do we--",
    "start": "2277800",
    "end": "2283860"
  },
  {
    "text": "know that there's a lot of cost\nin the health care industry and this system, the structure\nthey have isn't perfect.",
    "start": "2283860",
    "end": "2289220"
  },
  {
    "text": "And so how do we create a system\nso that these problems that need to get solved but don't\nhave economic incentive",
    "start": "2289220",
    "end": "2294240"
  },
  {
    "text": "because they're\nnot blockbusters, how do you combine NIH with\nmaybe some DARPA-like abilities and industry?",
    "start": "2294240",
    "end": "2300750"
  },
  {
    "text": "And if anybody's specialty\nis higher research, it would be interesting\nto get your insight first.",
    "start": "2300750",
    "end": "2306770"
  },
  {
    "text": " AUDIENCE: What you mean\nby higher research?",
    "start": "2306770",
    "end": "2312210"
  },
  {
    "text": "AUDIENCE: Well,\nif you're focusing on an academic career\nin a national lab,",
    "start": "2312210",
    "end": "2317980"
  },
  {
    "text": "you know more about\nthat than I would. AUDIENCE: Where is\nLilly when you need her? AUDIENCE: Yes, you got it. ",
    "start": "2317980",
    "end": "2326390"
  },
  {
    "text": "AUDIENCE: Yeah, I\nthink you probably, as Cooke-Deegan laid it out,\nyou just really struggle",
    "start": "2326390",
    "end": "2332150"
  },
  {
    "text": "in this peer review process\nif you have an idea for maybe not a blockbuster drug\nbut a new approach",
    "start": "2332150",
    "end": "2339680"
  },
  {
    "text": "to a system that hasn't\nreally been tried out yet. So that's what you see. [INAUDIBLE] a mentor\nhave this huge problem.",
    "start": "2339680",
    "end": "2346490"
  },
  {
    "text": "And I think it\nreally is just kind of allocating a part\nof that NIH budget",
    "start": "2346490",
    "end": "2353120"
  },
  {
    "text": "that they get to this\nDARPA-like high-impact, maybe high-risk research and\nthen moving from there.",
    "start": "2353120",
    "end": "2362410"
  },
  {
    "text": "But I'm not sure\nbecause it takes so long to develop these\nthings, so a three to five year.",
    "start": "2362410",
    "end": "2368953"
  },
  {
    "text": "And then you have to figure\nout clinical trials and things like that like. Would the time scale\nneed to be adjusted",
    "start": "2368953",
    "end": "2374430"
  },
  {
    "text": "to account for\ndoing the research and then moving\ninto clinical trials to be able to actually support\nthese high-risk initiatives.",
    "start": "2374430",
    "end": "2381839"
  },
  {
    "text": "And a lot of these\nI feel like will be building on research\nthat doesn't really exist or isn't really there yet. So we'll need more time\nto stand up [INAUDIBLE]..",
    "start": "2381840",
    "end": "2390803"
  },
  {
    "text": "AUDIENCE: Yeah, I\nthink there's probably two main ways that maybe\nsome of the later readings touch on more.",
    "start": "2390803",
    "end": "2396109"
  },
  {
    "text": "But definitely,\nincentives on the FDA is hard to extend and make\nthat process a little bit more",
    "start": "2396110",
    "end": "2404109"
  },
  {
    "text": "profitable than, say, if it's\non an orphan drug where you have a very small market that\ncould be addressed when",
    "start": "2404110",
    "end": "2412660"
  },
  {
    "text": "the drug comes out by\nincreasing the patent life so they have extended\npatent provisions",
    "start": "2412660",
    "end": "2419019"
  },
  {
    "text": "for those kind of drugs. That definitely helps\nmake it more profitable.",
    "start": "2419020",
    "end": "2424060"
  },
  {
    "text": "And also, a lot of the later\npapers talk about this. But they have a\nlot of flexibility",
    "start": "2424060",
    "end": "2430390"
  },
  {
    "text": "in the way they can\nprice their drugs. So I think that kind of helps a\nlot because if they can charge",
    "start": "2430390",
    "end": "2437710"
  },
  {
    "text": "a lot of money for a niche\ndrug that kind of compensates",
    "start": "2437710",
    "end": "2443050"
  },
  {
    "text": "for the fact that you're not\ngiving it to as many people. AUDIENCE: And I guess my\nconcern with that last one",
    "start": "2443050",
    "end": "2448690"
  },
  {
    "text": "is what about a Martin\nShkreli situation? AUDIENCE: I mean, yeah. Obviously, that's\ngoing to come up",
    "start": "2448690",
    "end": "2453940"
  },
  {
    "text": "because all these\ncompanies will want to recoup their costs\nbecause they're spending millions and billions of dollars\non these drugs to develop them.",
    "start": "2453940",
    "end": "2462180"
  },
  {
    "text": "And there is kind of an\nargument for both ways that it's kind of justified\nbut, I mean, obviously, bad",
    "start": "2462180",
    "end": "2468010"
  },
  {
    "text": "for society. AUDIENCE: And also, you could\nmake a very similar argument",
    "start": "2468010",
    "end": "2474040"
  },
  {
    "text": "for any other drug in one\nof these blockbuster drugs as we say. Because well, you\ncan still charge",
    "start": "2474040",
    "end": "2481089"
  },
  {
    "text": "an exorbitant price for them. You can get tons\nof money for them. And then you're back to\nsquare 1 where, OK, let's just",
    "start": "2481090",
    "end": "2487154"
  },
  {
    "text": "keep funding the\ndrugs that we've been doing because don't fix\nwhat isn't broken, right?",
    "start": "2487155",
    "end": "2493380"
  },
  {
    "text": "So I'm not sure how it would\nincentivize people to focus",
    "start": "2493380",
    "end": "2499140"
  },
  {
    "text": "on these smaller drugs. Now, one way you could do\nit, maybe tax incentives",
    "start": "2499140",
    "end": "2504570"
  },
  {
    "text": "or something. Maybe force insurance companies\nto foot the bill a bit more. But I don't really know the\ndetail on how that would work.",
    "start": "2504570",
    "end": "2513177"
  },
  {
    "text": "WILLIAM BONVILLIAN: This is one\nof the great societal dilemmas that we've get in health\ncare at the moment. You want to create enormous\nincentives for researchers",
    "start": "2513177",
    "end": "2523050"
  },
  {
    "text": "and the biotech\ncompanies they may create to go after these big problems. You really want to\nincentivize that process.",
    "start": "2523050",
    "end": "2531279"
  },
  {
    "text": "So if you start to\ndisincentivize it, you're going to have less\nremedies on the table.",
    "start": "2531280",
    "end": "2537030"
  },
  {
    "text": "On the other hand, you've\ngot serious cost problems for some portion of\nthe population that's",
    "start": "2537030",
    "end": "2542610"
  },
  {
    "text": "not going to be able to cope\nwith the cost structure. And you're going to\nhave real reluctance on the part of\ngovernment agencies",
    "start": "2542610",
    "end": "2548220"
  },
  {
    "text": "to subscribe for a\nhuge cost burden that only helps a relatively\nsmall number of people.",
    "start": "2548220",
    "end": "2555329"
  },
  {
    "text": "So this is a dilemma that\nis now upon us big time that we have not sorted\nthrough in an intelligent way.",
    "start": "2555330",
    "end": "2562680"
  },
  {
    "text": "And there's constant reviling\nof drug and biotech companies.",
    "start": "2562680",
    "end": "2569500"
  },
  {
    "text": "But on the other\nhand, they're the ones that created these\nopportunities for us. So it's a very contradictory--",
    "start": "2569500",
    "end": "2575400"
  },
  {
    "text": "the politics doesn't seem\nto recognize the importance of the innovation system. And yet we don't have the\nright balance between the two.",
    "start": "2575400",
    "end": "2583556"
  },
  {
    "text": "AUDIENCE: Yeah, [? I was just going to answer ?]\n[INAUDIBLE] the policy side, or whatever\n[? you want to say. ?] AUDIENCE: Oh, I\nactually was going to say that also I think the\ndimension that's also missing",
    "start": "2583556",
    "end": "2590307"
  },
  {
    "text": "is something we touched\non last week, which is the ethical components. I think there's really a rising\nbioethics community surrounding",
    "start": "2590308",
    "end": "2596300"
  },
  {
    "text": "issues of utilitarianism versus\nissues of human suffering. Do we seek to address\nthe person who",
    "start": "2596300",
    "end": "2602290"
  },
  {
    "text": "is suffering the most\nor the number of people who are suffering? And that is a really\ndifficult, I think,",
    "start": "2602290",
    "end": "2609830"
  },
  {
    "text": "ethical question\nthat has yet to be addressed on a national level. And I think it's easier--",
    "start": "2609830",
    "end": "2618575"
  },
  {
    "text": " I guess, I think about it\nin terms of heuristics, like short cuts for\ndecision making.",
    "start": "2618575",
    "end": "2625460"
  },
  {
    "text": "If we understand what our\nvalues are nationally, we can understand where to\nbegin to allocate money.",
    "start": "2625460",
    "end": "2631150"
  },
  {
    "text": "And if we sort out\nour national values in terms of the life\nsciences and what",
    "start": "2631150",
    "end": "2636609"
  },
  {
    "text": "we think are our\nnational priorities, perhaps maybe through a\nreferendum-like system,",
    "start": "2636610",
    "end": "2641873"
  },
  {
    "text": "I think it would\nactually be a much more efficient and accountable\nway for the government to make funding\npriority decisions",
    "start": "2641873",
    "end": "2648740"
  },
  {
    "text": "rather than for life sciences\norganizations and the NIH to sort of make those\ndecisions for themselves",
    "start": "2648740",
    "end": "2655420"
  },
  {
    "text": "or for the citizens. Because ultimately, this is\nan issue at the human level.",
    "start": "2655420",
    "end": "2662079"
  },
  {
    "text": "And that implies\nan understanding of bioethical considerations.",
    "start": "2662080",
    "end": "2667308"
  },
  {
    "text": "WILLIAM BONVILLIAN: I think that\ntends to run into a problem, however, with root attitudes\nof the American population.",
    "start": "2667308",
    "end": "2673570"
  },
  {
    "text": "And I would say that a lot\nof the American population believes that we should\nbe allowed to live forever",
    "start": "2673570",
    "end": "2678820"
  },
  {
    "text": "because we're Americans. So we should be eternal. I'm exaggerating a bit here.",
    "start": "2678820",
    "end": "2684640"
  },
  {
    "text": "But there's a lot\nof thinking along those lines and a\nlot of assumptions that any cost, whatever it\nis, is justified in terms",
    "start": "2684640",
    "end": "2693520"
  },
  {
    "text": "of the outcome for my health. So these are these are\nreally tough decisions.",
    "start": "2693520",
    "end": "2699760"
  },
  {
    "text": "And the life science system\nis now right up against this. And the whole innovation model\nis right up against these.",
    "start": "2699760",
    "end": "2704940"
  },
  {
    "text": "So these are these are\nimportant considerations. AUDIENCE: Yeah.",
    "start": "2704940",
    "end": "2710180"
  },
  {
    "text": "Just my concern with the\nproposal as far as putting it in the hands of\nAmerican people is",
    "start": "2710180",
    "end": "2717349"
  },
  {
    "text": "kind of what questions are\nappropriate for letting people to be answering versus\nthe ones that are experts.",
    "start": "2717350",
    "end": "2723925"
  },
  {
    "text": "[INAUDIBLE] A lot\nof people would debate that the Brexit\nquestion wasn't really something that the average\nperson could understand",
    "start": "2723925",
    "end": "2730400"
  },
  {
    "text": "well enough to make\nan informed decision. And so I guess if\nyou're asking strictly what are your ethical\nbeliefs, vote on that.",
    "start": "2730400",
    "end": "2736670"
  },
  {
    "text": "I guess that's something\nthat people can vote on. But if you're given\noptions of should we fund something that will save x\nnumber of people at this cost,",
    "start": "2736670",
    "end": "2745250"
  },
  {
    "text": "weighing that information is\nmore difficult than I think the average person is willing to\nput the time in to understand.",
    "start": "2745250",
    "end": "2751640"
  },
  {
    "text": "So I think that,\nto some extent, NIH and these kind of\norganizations need to make the decisions on what\nour national priorities are",
    "start": "2751640",
    "end": "2759580"
  },
  {
    "text": "but, ideally, with\nsome input from us. WILLIAM BONVILLIAN:\nI want to push you back to the issue that's\nbefore us in this class, which",
    "start": "2759580",
    "end": "2768440"
  },
  {
    "text": "is the innovation organization\nmodel that we've got here. So we're looking at an\ninnovation organization that",
    "start": "2768440",
    "end": "2775069"
  },
  {
    "text": "evolved in a very\nhistorical set of ways where the problems, when\nit was in the foundation level, the scientific\nproblems turned out",
    "start": "2775070",
    "end": "2782960"
  },
  {
    "text": "to be different than\nthe way we see them now. We tend to see that\nthere are a lot",
    "start": "2782960",
    "end": "2789350"
  },
  {
    "text": "of cross-cutting\nscientific approaches that cut across many\ndisease pathways that may",
    "start": "2789350",
    "end": "2794870"
  },
  {
    "text": "be critical for those diseases. Whereas back then,\nwe saw, oh, there will be one remedy\nfor each disease,",
    "start": "2794870",
    "end": "2802730"
  },
  {
    "text": "a much earlier-stage\nscientific notion of disease. And we're caught\nup in that model.",
    "start": "2802730",
    "end": "2808070"
  },
  {
    "text": "And how do we bring change here? We're up against a\nlegacy-sector problem",
    "start": "2808070",
    "end": "2814895"
  },
  {
    "text": "as we'll talk in a little bit. How do we bring change\nto that legacy sector",
    "start": "2814895",
    "end": "2820900"
  },
  {
    "text": "from an organizational\npoint of view? AUDIENCE: I have not an\nanswer, but a non-answer.",
    "start": "2820900",
    "end": "2827650"
  },
  {
    "text": "I am going back to the attack\non peer review as it were. I think that's a very odd place\nto start in terms of something",
    "start": "2827650",
    "end": "2836727"
  },
  {
    "text": "to get rid of. I think there were definitely\na lot of reasonable arguments",
    "start": "2836727",
    "end": "2842500"
  },
  {
    "text": "presented in favor of adopting\nsomething a DARPA model. And then going back\nto your ethics--",
    "start": "2842500",
    "end": "2847510"
  },
  {
    "text": "you raised the point of\nbioethics considerations. It seems to me that peer\nreview in the system,",
    "start": "2847510",
    "end": "2853290"
  },
  {
    "text": "appearing to be the\nvalues of peer review, are so deeply ingrained\nin the biopharmaceutical--",
    "start": "2853290",
    "end": "2859960"
  },
  {
    "text": "well, more on the biological\nand medical research community. It seems like it's very\nmuch part of their values.",
    "start": "2859960",
    "end": "2866770"
  },
  {
    "text": "And it would be very\nodd to me to see them as separated out\nbecause I can recognize all of the detriments of\nthe peer review system",
    "start": "2866770",
    "end": "2873260"
  },
  {
    "text": "and how it can\nfavor incremental, unimportant research over big\ninnovations and risk takers.",
    "start": "2873260",
    "end": "2882099"
  },
  {
    "text": "But it still seems like,\nif you remove that barrier, then you might have a\nflood of ethical problems",
    "start": "2882100",
    "end": "2887200"
  },
  {
    "text": "that would just\nstart cropping up. WILLIAM BONVILLIAN:\nLook, I mean, the DARPA model does not\nwork in all circumstances.",
    "start": "2887200",
    "end": "2893770"
  },
  {
    "text": "In other words, the DARPA model\nis very much a top-down model. A bunch of elite\nprogram managers",
    "start": "2893770",
    "end": "2900579"
  },
  {
    "text": "are looking at\nthings they want out of the end of the\ninnovation pipeline and designing\nprojects to get there.",
    "start": "2900580",
    "end": "2908940"
  },
  {
    "text": "And we can certainly see why\nthere's room for this model, for that kind of projects-based,\nchallenge-based model.",
    "start": "2908940",
    "end": "2915750"
  },
  {
    "text": "NIH offers the other\nside of the coin. Researchers propose\nfunding, and they",
    "start": "2915750",
    "end": "2921359"
  },
  {
    "text": "get funded based upon the\ninterest and quality of what they're proposing. That's very much\na bottom-up model.",
    "start": "2921360",
    "end": "2927770"
  },
  {
    "text": "In other words, a lot of\npeople can see a lot of stuff in the bottom level\nthat a top-down model can't necessarily see.",
    "start": "2927770",
    "end": "2934109"
  },
  {
    "text": "So Chloe, you're right. It's not that you want to\nreplace NIH with DARPA.",
    "start": "2934110",
    "end": "2940799"
  },
  {
    "text": "I think what Robert\nCooke-Deegan would say is maybe there's\nroom within a large NIH",
    "start": "2940800",
    "end": "2947619"
  },
  {
    "text": "entity for a DARPA like piece. Just as there is in the\nDefense Innovation System,",
    "start": "2947620",
    "end": "2953320"
  },
  {
    "text": "DARPA is only one element of\na much larger defense research portfolio. But it does provide some\ninteresting capability.",
    "start": "2953320",
    "end": "2960290"
  },
  {
    "text": " And peer review\ndoes have advantages",
    "start": "2960290",
    "end": "2969880"
  },
  {
    "text": "from that bottom-up perspective\nthat a top-down strong program manager perspective will not\nnecessarily be able to capture.",
    "start": "2969880",
    "end": "2976990"
  },
  {
    "text": " AUDIENCE: So from a\nbusiness perspective,",
    "start": "2976990",
    "end": "2982955"
  },
  {
    "text": "the thing I'm\nwondering about is-- because there is this\ntrend right now called social bonds, which\nwhat they do is they look at the parts of\nsociety that are really wasting",
    "start": "2982955",
    "end": "2990200"
  },
  {
    "text": "a lot of money and\nthen they create businesses to solve them. And then they give a return.",
    "start": "2990200",
    "end": "2996850"
  },
  {
    "text": "That's why I asked about\nthe blockbuster drug. Because you get to\nfind a blockbuster drug is also a drug that\nreduces a ton of costs",
    "start": "2996850",
    "end": "3002830"
  },
  {
    "text": "for the government. And the business model is\nthe government is saying, oh, we're spending $100 million\nhere to solve this problem.",
    "start": "3002830",
    "end": "3008410"
  },
  {
    "text": "We're going to send some of that\nportion of the money to you. And that's a good\nway to cut the fat.",
    "start": "3008410",
    "end": "3014500"
  },
  {
    "text": "Because if the major\nproblem is we're going to use all our budget\nto solve these diseases-- there's probably a disease\nthat's 80% or a huge proportion",
    "start": "3014500",
    "end": "3022887"
  },
  {
    "text": "because it's not going to\nbe a linear relationship with the cost. My other concern\ntoo was when you",
    "start": "3022887",
    "end": "3028180"
  },
  {
    "text": "said that they\ndoubled the budget, this happens a lot in software. So it's hard and\nunintuitive to understand.",
    "start": "3028180",
    "end": "3033880"
  },
  {
    "text": "But it's like, say we're\ngoing to have the lunch. And I say, our\nbudget is $100,000.",
    "start": "3033880",
    "end": "3039040"
  },
  {
    "text": "Then I have to justify-- WILLIAM BONVILLIAN: That\nwould be quite a lunch. AUDIENCE: Yeah, that's the\nthing because we're not just",
    "start": "3039040",
    "end": "3044529"
  },
  {
    "text": "eating, right? It's like, OK, now, we have\nto justify the $100,000.",
    "start": "3044530",
    "end": "3049690"
  },
  {
    "text": "Or a cool example\nis right now there is a startup in Silicon Valley\nthat spent like $120 million to develop a juicer.",
    "start": "3049690",
    "end": "3055540"
  },
  {
    "text": "And so that you could only\njuice with the machine. And then a reporter was\nlike, I call your bluff.",
    "start": "3055540",
    "end": "3062387"
  },
  {
    "text": "And they squeezed\nit with their hands. And they did it. So my concern is when\nyou have too much money,",
    "start": "3062387",
    "end": "3068170"
  },
  {
    "text": "you tend to have\nto justify things. And you come up with\nthis weird logic tree. And you don't really\nfundamentally solve",
    "start": "3068170",
    "end": "3073390"
  },
  {
    "text": "the problem. In code, if there's a piece\ncode that one coder could do and you put five people,\nit actually complicates it.",
    "start": "3073390",
    "end": "3079007"
  },
  {
    "text": "It makes it way harder. And now, you got\npeople infighting. So that was my big\nconcern with that too.",
    "start": "3079007",
    "end": "3085770"
  },
  {
    "text": "AUDIENCE: I think-- and Martin\nmay be trying to get at it. This kind of group\ntheory doesn't really",
    "start": "3085770",
    "end": "3091080"
  },
  {
    "text": "exists or kind of\nbreaks down in NIH because it's really hard\nto get these cross-cutting technologies and encourage\nthat collaboration.",
    "start": "3091080",
    "end": "3098140"
  },
  {
    "text": "And I think what I really\nwant to see out of the DARPA that they pull is not so much\nget rid of the peer review",
    "start": "3098140",
    "end": "3105099"
  },
  {
    "text": "but start-- because DARPA has the ability\nto pull these great groups",
    "start": "3105100",
    "end": "3110130"
  },
  {
    "text": "together and just call on\na lot of different folks from a lot of different\nareas and then direct them towards a specific\nresearch problem.",
    "start": "3110130",
    "end": "3118500"
  },
  {
    "text": "And I think where NIH\nstruggles is, yeah, they might have a call\nto say we want to get rid of cancer or heart disease.",
    "start": "3118500",
    "end": "3125442"
  },
  {
    "text": "But there are a lot of\ndifferent folks working on it. And not a lot of them, I would\nsay, probably work together",
    "start": "3125442",
    "end": "3131880"
  },
  {
    "text": "in tandem to really\nfigure out and solve maybe one aspect of that\nproblem for maybe 10 years.",
    "start": "3131880",
    "end": "3138540"
  },
  {
    "text": "And then they focus\non a different aspect of how a disease would\nwork in a different lab.",
    "start": "3138540",
    "end": "3143670"
  },
  {
    "text": "And I think NIH really\nstruggles in pulling together these cross-cutting\ntechnologies because there's",
    "start": "3143670",
    "end": "3149070"
  },
  {
    "text": "no one pulling them together. And they just leave it up to the\ndiscretion of the researchers",
    "start": "3149070",
    "end": "3156350"
  },
  {
    "text": "and scientists and\npharmaceutical companies to come up with\nincremental advances rather than not only calling\nfor big calls or big research",
    "start": "3156350",
    "end": "3167730"
  },
  {
    "text": "projects but also\nfunding and making it possible for great groups\nto work on these research projects.",
    "start": "3167730",
    "end": "3173400"
  },
  {
    "text": "AUDIENCE: Max WILLIAM BONVILLIAN:\nMartin, you want to give us some closing\nthoughts on these two pieces? Oh, I'm sorry, Max. Did you--",
    "start": "3173400",
    "end": "3178890"
  },
  {
    "text": "AUDIENCE: I actually\nhad a quick question. So given that this was published\n21 years ago, give or take,",
    "start": "3178890",
    "end": "3187020"
  },
  {
    "text": "I'm curious-- WILLIAM BONVILLIAN: Robert\nCooke-Deegan's piece, you mean. AUDIENCE: Yeah. Did NIH ever attempt\nanything like this?",
    "start": "3187020",
    "end": "3194050"
  },
  {
    "text": "Because we've had some\nsignificant time period. Did they at least look at it? Or did they decide, no? AUDIENCE: And also, how\nmuch criticism did he",
    "start": "3194050",
    "end": "3200740"
  },
  {
    "text": "get for publishing that? WILLIAM BONVILLIAN: It\nwas a threatening piece to the NIH and life\nscience community,",
    "start": "3200740",
    "end": "3209359"
  },
  {
    "text": "frankly, arguing that there may\nbe an additional model that you all need to consider.",
    "start": "3209360",
    "end": "3215480"
  },
  {
    "text": "So it was not received\nwith open arms. Now, in fact, the current\nNIH director, Collins,",
    "start": "3215480",
    "end": "3226010"
  },
  {
    "text": "has, early on in his\ntenure as director, latched onto the\nproblem that NIH",
    "start": "3226010",
    "end": "3232400"
  },
  {
    "text": "has got in doing translational\nwork-- in other words, moving a technology\nfrom the basic stage into follow-on sectors\nand doing the handoff",
    "start": "3232400",
    "end": "3239990"
  },
  {
    "text": "to the private sector. So Collins began to\nfocus on that problem. And there was discussion, at\nthat time, of doing something",
    "start": "3239990",
    "end": "3248450"
  },
  {
    "text": "like a DARPA. So his effort to create NCATS\nto do translational medicine,",
    "start": "3248450",
    "end": "3254030"
  },
  {
    "text": "the director that he hired\nto head that new institute-- and he had to close\nanother one to do it-- ",
    "start": "3254030",
    "end": "3262630"
  },
  {
    "text": "actually really began\nthinking seriously about should there be DARPA-like\nelements in this new NCATS",
    "start": "3262630",
    "end": "3269080"
  },
  {
    "text": "entity. Chris Austin who\nis that director, very talented and very\ninteresting person, however,",
    "start": "3269080",
    "end": "3278289"
  },
  {
    "text": "just didn't have the resource\nto set up a whole new entity within his NCATS piece.",
    "start": "3278290",
    "end": "3284560"
  },
  {
    "text": "But so it's an\nidea that continues to kick around here and there. And frankly, I would view it\nas an interesting additional",
    "start": "3284560",
    "end": "3292390"
  },
  {
    "text": "feature for NIH to do some\nthings that it can't really do without this kind of\norganizational model.",
    "start": "3292390",
    "end": "3299920"
  },
  {
    "text": "So I think there's\norganizational lessons here that we can take from the\nissues we've been reviewing",
    "start": "3299920",
    "end": "3305590"
  },
  {
    "text": "and apply it to a long\nestablished research entity",
    "start": "3305590",
    "end": "3311500"
  },
  {
    "text": "to create new\nthings in the model. How about some closing\nthoughts, Martine?",
    "start": "3311500",
    "end": "3317147"
  },
  {
    "text": "AUDIENCE: I mean,\nthe closing thoughts is that we discussed\nthe NIH model and how it does work\nfor what they're doing",
    "start": "3317147",
    "end": "3322780"
  },
  {
    "text": "but also how there are a\nlot of blind spots and areas that aren't being touched into\nI've been trying to solve.",
    "start": "3322780",
    "end": "3329483"
  },
  {
    "text": "And then we discussed\nDARPA, which might be a good way of solving it. But it seems like it won't\nfit in well with NIH.",
    "start": "3329483",
    "end": "3336250"
  },
  {
    "text": "But there is a structural\ndissonance, I would say, in terms of that this\nform factor does not work",
    "start": "3336250",
    "end": "3341920"
  },
  {
    "text": "for these kinds of problems. And it might also\nbe the groupthink",
    "start": "3341920",
    "end": "3347200"
  },
  {
    "text": "in the area that affects\ntheir ability to solve these kinds of problems. So it might be better\nfor there to be a DARPA",
    "start": "3347200",
    "end": "3353440"
  },
  {
    "text": "NIH but not at NIH or nearby\nbecause it might be too difficult. And also, how do\nyou create natural incentives",
    "start": "3353440",
    "end": "3360099"
  },
  {
    "text": "for the researchers. Because it seems like they\ndo these kind of leapfrogging",
    "start": "3360100",
    "end": "3365109"
  },
  {
    "text": "research initiatives\nbecause it's a lot simpler and they have a lot to\nlose if they do fail.",
    "start": "3365110",
    "end": "3370270"
  },
  {
    "text": "And so how do you create\nthis kind of comfort zone for researchers so that,\neven if they do fail,",
    "start": "3370270",
    "end": "3375550"
  },
  {
    "text": "to get some kind of reward? And how do they get recognition\nfor that sacrifice of their",
    "start": "3375550",
    "end": "3381017"
  },
  {
    "text": "what you call \"academic career.\"  WILLIAM BONVILLIAN: Right. I mean, that's\nanother issue too,",
    "start": "3381017",
    "end": "3388230"
  },
  {
    "text": "which is having multiple\nPIs on the problem. It's complicated in\nan RO1 award process",
    "start": "3388230",
    "end": "3395460"
  },
  {
    "text": "that focuses on the single PI. Let me go onto the next\ncouple of readings.",
    "start": "3395460",
    "end": "3401850"
  },
  {
    "text": "And we'll do them as a pair. So the Infectious Disease\nSociety of America",
    "start": "3401850",
    "end": "3407280"
  },
  {
    "text": "has this report called Bad Bugs,\nNo Drugs, which essentially summarizes the whole problem.",
    "start": "3407280",
    "end": "3414750"
  },
  {
    "text": "And then the Food and\nDrug Administration has a paper on\ninnovation or stagnation,",
    "start": "3414750",
    "end": "3420569"
  },
  {
    "text": "which focuses on some of\nthe problems they face. So let's do those.",
    "start": "3420570",
    "end": "3428580"
  },
  {
    "text": "And Chloe, do you have those? Or Martin, do to\nhave one of those? AUDIENCE: Do you have-- I know I have--",
    "start": "3428580",
    "end": "3433630"
  },
  {
    "text": "AUDIENCE: Which one? WILLIAM BONVILLIAN:\nBad Bugs, No Drugs, the Infectious Disease Society? ",
    "start": "3433630",
    "end": "3439986"
  },
  {
    "text": "AUDIENCE: I can do this one.  I'm prepared for it, yeah.",
    "start": "3439986",
    "end": "3445970"
  },
  {
    "text": "WILLIAM BONVILLIAN: All right. Well, Chloe, which\none do you have? You have the FDA one? Innovation, stagnation. All right, fine. OK.",
    "start": "3445970",
    "end": "3453340"
  },
  {
    "text": "I mean, the title\ngives this story away. And this is the Infectious\nDisease Society.",
    "start": "3453340",
    "end": "3458800"
  },
  {
    "text": "And they note that resistance\nto bacteria, I think,",
    "start": "3458800",
    "end": "3468280"
  },
  {
    "text": "as everybody in this classroom\nknows is very much on the rise. ",
    "start": "3468280",
    "end": "3474355"
  },
  {
    "text": "And again, this report was\nwritten a few years ago. Two million people\nin US hospitals are going to get bacterial\ninfections in the hospital.",
    "start": "3474355",
    "end": "3480400"
  },
  {
    "text": "And 90,000 of them\nare going to die. That is a staggering\nnumber, right?",
    "start": "3480400",
    "end": "3489310"
  },
  {
    "text": "We lose 30,000 people a year\nin automobile accidents.",
    "start": "3489310",
    "end": "3494320"
  },
  {
    "text": "We're losing three times\nthat many in hospitals. So talk about\ntolerance for risk.",
    "start": "3494320",
    "end": "3501280"
  },
  {
    "text": "Americans haven't\nfully woken up to this. So hospitals are increasingly\na dangerous place to be.",
    "start": "3501280",
    "end": "3508420"
  },
  {
    "text": "And only two classes\nof antibiotics",
    "start": "3508420",
    "end": "3514119"
  },
  {
    "text": "have been developed at\nthe time this was written in the previous 30 years. And one of those is\nalready facing resistance",
    "start": "3514120",
    "end": "3519549"
  },
  {
    "text": "in this kind of endless\ncycle of build up of resistance that bacterial\nsources go through.",
    "start": "3519550",
    "end": "3528339"
  },
  {
    "text": "And by the late 1960s,\n80% of staff bacteria",
    "start": "3528340",
    "end": "3535420"
  },
  {
    "text": "were penicillin resistant. And in pneumonia,\n40% of the infections",
    "start": "3535420",
    "end": "3540910"
  },
  {
    "text": "were resistant to one drug\nand 15% to the next three.",
    "start": "3540910",
    "end": "3545920"
  },
  {
    "text": "So this is a serious\ngrowing problem. Yet because of the\nblockbuster drug model,",
    "start": "3545920",
    "end": "3555650"
  },
  {
    "text": "there's no incentive for\ndrug companies or biotechs to go after these antibiotics\nbecause they cure the problem.",
    "start": "3555650",
    "end": "3565790"
  },
  {
    "text": " So you take the\nantibiotic for two weeks, and the problem is solved.",
    "start": "3565790",
    "end": "3571880"
  },
  {
    "text": "What you want, under the\nblockbuster drug model, is something that\nI'm going to have",
    "start": "3571880",
    "end": "3577100"
  },
  {
    "text": "to take for the rest of my life\nfor $100,000 a year, right? You don't really\nwant to cure it.",
    "start": "3577100",
    "end": "3582319"
  },
  {
    "text": "You want to create\nincremental advances that manage the problem. Whereas the antibiotic\nactually cures the problem.",
    "start": "3582320",
    "end": "3591260"
  },
  {
    "text": "So there's very little\nincentive since there's no economic return\nmodel that works.",
    "start": "3591260",
    "end": "3597122"
  },
  {
    "text": "There's very little\nincentive to go after these antibiotic problems. They work too well too fast.",
    "start": "3597122",
    "end": "3603260"
  },
  {
    "text": "So it's a very weak\nreturn on investment. And successful\nantibiotics are just",
    "start": "3603260",
    "end": "3608720"
  },
  {
    "text": "too successful to justify\nthe investment cost. So everybody is aware of this.",
    "start": "3608720",
    "end": "3615349"
  },
  {
    "text": "Elias Zerhouni, who preceded\nFrancis Collins as head of NIH,",
    "start": "3615350",
    "end": "3622460"
  },
  {
    "text": "had this roadmap model. And this was certainly on that\nlist of cross-cutting issues",
    "start": "3622460",
    "end": "3627530"
  },
  {
    "text": "that need to be dealt with. But how do you get\naround the kind of model here, the economic,\nproblematic blockbuster drug",
    "start": "3627530",
    "end": "3635690"
  },
  {
    "text": "model here? So I mean there've been a\nvariety of ideas advanced.",
    "start": "3635690",
    "end": "3641779"
  },
  {
    "text": "There was bioshield legislation\nto deal with biothreats. But it could also bear\non infectious diseases.",
    "start": "3641780",
    "end": "3649609"
  },
  {
    "text": "The idea there was,\nfor a biothreat, why would anybody develop\na biothreat remedy?",
    "start": "3649610",
    "end": "3656789"
  },
  {
    "text": "Because the drug\nwould only be sold if there was a\ncompletely unpredictable",
    "start": "3656790",
    "end": "3663369"
  },
  {
    "text": "terrible national disaster. So are you going to take\nall the risks and go through the $1.4-billion clinical trial\nprocess to develop a remedy",
    "start": "3663370",
    "end": "3672110"
  },
  {
    "text": "for something that may\nwell never be used? A similar kind of problem\nfor antibiotic drugs.",
    "start": "3672110",
    "end": "3679369"
  },
  {
    "text": "So the Infectious Disease\nSociety said, wait a minute. The same model that would\ndeal with biothreats, which",
    "start": "3679370",
    "end": "3686480"
  },
  {
    "text": "is that the\ngovernment would agree to buy a certain\nnumber of dosages,",
    "start": "3686480",
    "end": "3692279"
  },
  {
    "text": "a certain volume of\nthe remedy, at a set price if you\ndeveloped the remedy.",
    "start": "3692280",
    "end": "3699752"
  },
  {
    "text": "So the risk on the\npart of the government is actually pretty low. It only has to buy something\nif you solve the problem.",
    "start": "3699752",
    "end": "3705660"
  },
  {
    "text": "But then of course, that's\nwhat biotechs do anyway. That's the economic\nmodel they work off of. So could the government\nintervene in this sector",
    "start": "3705660",
    "end": "3712710"
  },
  {
    "text": "and, in effect, really change\naround the risk-reward model. So ideas like this\ncome to bear here.",
    "start": "3712710",
    "end": "3719953"
  },
  {
    "text": "We certainly haven't\nsolved this problem and remains very much\nwith us but illustrates what the issues are.",
    "start": "3719953",
    "end": "3726030"
  },
  {
    "text": "This other report from the\nFDA, Innovation/Stagnation-- Challenge and Opportunity\non the Critical Path to New Medical Products.",
    "start": "3726030",
    "end": "3734220"
  },
  {
    "text": "And both these reports, by\nthe way, have been updated. I put the originals in, which\nare fairly hard-hitting.",
    "start": "3734220",
    "end": "3739320"
  },
  {
    "text": "But they've been updated since\nthen by these organizations so you can get later versions. ",
    "start": "3739320",
    "end": "3747740"
  },
  {
    "text": "FDA does not have its own\nsubstantial research arm. NIH does the medical research.",
    "start": "3747740",
    "end": "3755430"
  },
  {
    "text": "Yet we're not doing\nresearch on how",
    "start": "3755430",
    "end": "3763040"
  },
  {
    "text": "to get a better, more reliable,\nand certainly speedier",
    "start": "3763040",
    "end": "3770240"
  },
  {
    "text": "evaluation and approval\nprocess for FDA. We don't have that. There's nobody on that problem.",
    "start": "3770240",
    "end": "3776900"
  },
  {
    "text": "NIH does not view\nthat is their problem. They view their\nproblem as developing new drugs, new therapies, not\nfiguring out a safety approval",
    "start": "3776900",
    "end": "3785780"
  },
  {
    "text": "set of problems. So nobody's really\non that problem except for FDA's own fairly\nmodest research budget.",
    "start": "3785780",
    "end": "3794150"
  },
  {
    "text": "So the picture that\nthis report portrays is ongoing breakthrough\nscientific discoveries",
    "start": "3794150",
    "end": "3802520"
  },
  {
    "text": "that get nailed because the\ndrug approval process isn't",
    "start": "3802520",
    "end": "3807590"
  },
  {
    "text": "receiving new science\nand new technology advances that would\nenable it to keep up",
    "start": "3807590",
    "end": "3813088"
  },
  {
    "text": "with these breakthroughs. And we mentioned this earlier. But the most serious one that's\nahead is in precision medicine",
    "start": "3813088",
    "end": "3820310"
  },
  {
    "text": "and personalized medicine\nwhere it's developing a therapy or a remedy that's uniquely\nappropriate for you",
    "start": "3820310",
    "end": "3828530"
  },
  {
    "text": "as opposed to me, a\npersonalized medicine approach. How are we going to do the\napproval process for that?",
    "start": "3828530",
    "end": "3835520"
  },
  {
    "text": "How is FDA is going\nto manage that? So it is a dilemma\nhere in the system.",
    "start": "3835520",
    "end": "3846849"
  },
  {
    "text": "And again, it's an innovation\norganization problem. We've got an\ninnovation organization",
    "start": "3846850",
    "end": "3853160"
  },
  {
    "text": "that's focused on one\nset of the problems. And they've got the\nresources do the R&D on it. And yet we've got a\nparallel big problem that's",
    "start": "3853160",
    "end": "3860060"
  },
  {
    "text": "jeopardizing the other system. And we don't have the\norganizational capability of acting on it.",
    "start": "3860060",
    "end": "3865400"
  },
  {
    "text": "So then this is yet\nanother innovation organizational\nproblem that, when you think about these\nthings as systems,",
    "start": "3865400",
    "end": "3871310"
  },
  {
    "text": "you begin to identify\nwhat the gaps are. And here is one. That's probably\nenough on this topic.",
    "start": "3871310",
    "end": "3876785"
  },
  {
    "text": " So why don't we go right\ninto some Q&A on this.",
    "start": "3876785",
    "end": "3883830"
  },
  {
    "text": "Martine, you want to lead\nus on Bad Bugs, No Drugs? AUDIENCE: Yeah. ",
    "start": "3883830",
    "end": "3891849"
  },
  {
    "text": "So I guess the\nmain theme of this is their way of using policy\nor subsidies to incentivize the private sector to\ntake on this problem.",
    "start": "3891850",
    "end": "3899445"
  },
  {
    "text": "Or even is the private\nsector even the right entity to handle this problem? ",
    "start": "3899445",
    "end": "3909990"
  },
  {
    "text": "AUDIENCE: I feel like\na little suggestion of having government\nguarantee to pay",
    "start": "3909990",
    "end": "3915200"
  },
  {
    "text": "for a certain amount\nof dosages seems like a pretty good fix for it.",
    "start": "3915200",
    "end": "3920259"
  },
  {
    "text": "If you leave the free market\nalone, these companies, they currently don't\nhave an incentive.",
    "start": "3920260",
    "end": "3925900"
  },
  {
    "text": "So I don't think that's\nreally an option. AUDIENCE: A professor of\nmine, an economics professor",
    "start": "3925900",
    "end": "3932930"
  },
  {
    "text": "at Wellesley and Cornell is\nvery supportive of patent extensions, which is something\nthat was cited in the report.",
    "start": "3932930",
    "end": "3939450"
  },
  {
    "text": "And she felt like, at\nleast in my understanding, that would very much\nmotivate bio and pharma companies to do\nresearch primarily",
    "start": "3939450",
    "end": "3945780"
  },
  {
    "text": "because they're concerned\nthat their patents are going to run out in the\nlifecycle of the innovation process.",
    "start": "3945780",
    "end": "3951720"
  },
  {
    "text": "WILLIAM BONVILLIAN: And explain\nhow that would work, Steph? AUDIENCE: Oh, man, I don't know\nthat I could do it justice. WILLIAM BONVILLIAN:\nJust briefly.",
    "start": "3951720",
    "end": "3958970"
  },
  {
    "text": "Give us a snapshot. Or Chris. AUDIENCE: So I think,\nmy understanding of the patent-extension\nprocess is that,",
    "start": "3958970",
    "end": "3965820"
  },
  {
    "text": "especially for orphan drugs\nwhere it's like under like 10,000 people or\nsomething like that--",
    "start": "3965820",
    "end": "3972559"
  },
  {
    "text": "so a smaller market size\nor it's targeting children like adolescents, you\nget patent extensions.",
    "start": "3972560",
    "end": "3979279"
  },
  {
    "text": "And that could be three\nto five years extra, which is pretty significant\nin terms of drug companies.",
    "start": "3979280",
    "end": "3986810"
  },
  {
    "text": "And yeah, I think those\nare the main ones. And there's also breakthrough\ntherapy designations.",
    "start": "3986810",
    "end": "3993560"
  },
  {
    "text": "And those not only help speed\nup the approval process, which is really valuable for these\ncompanies that really want",
    "start": "3993560",
    "end": "3999050"
  },
  {
    "text": "to push through these\ndrugs really quickly and get it to market. And then they also extend a\nlittle bit in certain cases.",
    "start": "3999050",
    "end": "4007279"
  },
  {
    "text": "So there's a lot of\ndifferent small ways FDA is trying to\nget more incentive, which is nice to see.",
    "start": "4007280",
    "end": "4014050"
  },
  {
    "text": "I think it's a good policy. AUDIENCE: And to add\na lower-order analysis from microeconomics,\nI think the way",
    "start": "4014050",
    "end": "4022106"
  },
  {
    "text": "that she explained it was\nessentially-- and all of you may know this. I did not know this\nuntil two years ago.",
    "start": "4022106",
    "end": "4027400"
  },
  {
    "text": "So maybe this is\nnew to someone-- is that researchers,\nI mean, from the time",
    "start": "4027400",
    "end": "4033023"
  },
  {
    "text": "that they apply for\na patent, they have, what is it, 15, 17\nyears or something like that to\ncommercialization where",
    "start": "4033023",
    "end": "4038090"
  },
  {
    "text": "their patent is protected. AUDIENCE: I thought it was 20. AUDIENCE: 20? AUDIENCE: It changed. WILLIAM BONVILLIAN:\nYeah, it did. [INAUDIBLE] is now 20 from 17.",
    "start": "4038090",
    "end": "4045520"
  },
  {
    "text": "AUDIENCE: So it used to be 17. And now, it is 20. And so the way that\nshe explained it to us is that, because a lot of\nthe research-and-development",
    "start": "4045520",
    "end": "4055390"
  },
  {
    "text": "process could take\n20 years by the time they get a drug to\nmarket, they may have already lost the patent.",
    "start": "4055390",
    "end": "4061180"
  },
  {
    "text": "So it no longer becomes\neconomically advantageous for the company to\npursue commercialization",
    "start": "4061180",
    "end": "4067270"
  },
  {
    "text": "of a particular therapy, and\nthus what Chris was saying. So that's just sort of\nthe small connections.",
    "start": "4067270",
    "end": "4074140"
  },
  {
    "text": "AUDIENCE: Separate concerns\nsort of from like a scientific or a biological perspective.",
    "start": "4074140",
    "end": "4079910"
  },
  {
    "text": "So I wonder if, is it that\nthese drugs are super effective or antibiotics are\nthe best mechanism",
    "start": "4079910",
    "end": "4085690"
  },
  {
    "text": "to get rid of these\nbacteria in the way that we traditionally\nthink about them to say that one is the way that\nwe think about bacteria?",
    "start": "4085690",
    "end": "4094990"
  },
  {
    "text": "Is that the actual\nmost effective means? Or is that actually\nhow they work? Or do we not\nunderstand the pathways",
    "start": "4094990",
    "end": "4100089"
  },
  {
    "text": "of how they're\nactually becoming more resistant to these technologies? So my question, is there just\nlike a group think in a way",
    "start": "4100090",
    "end": "4110199"
  },
  {
    "text": "that we think about antibiotics\nand bacterial theory in biology or in medicine.",
    "start": "4110200",
    "end": "4119559"
  },
  {
    "text": "We're just kind of following\nalong the same path. So I would love to talk\nto a bacteriologist.",
    "start": "4119560",
    "end": "4124600"
  },
  {
    "text": "And then 2, is this problem\none that we will ever solve? Or will it just get\nexponentially worse?",
    "start": "4124600",
    "end": "4130509"
  },
  {
    "text": "Because I can imagine,\neven if we come up with a faster and\nfaster mechanism to get out these antibiotics\nand reach more people,",
    "start": "4130510",
    "end": "4136990"
  },
  {
    "text": "will these bacteria just\nkind of keep growing and get faster\nand more resistant and we'll always\nhave this problem?",
    "start": "4136990",
    "end": "4143710"
  },
  {
    "text": "And then thirdly,\ndoes that mean that we should have an established\nkind of entity within the FDA",
    "start": "4143710",
    "end": "4152680"
  },
  {
    "text": "that just deals with\nantibiotics if they deem it as a serious enough problem and\nit's going to be persistent?",
    "start": "4152680",
    "end": "4159680"
  },
  {
    "text": "AUDIENCE: [INAUDIBLE] AUDIENCE: Yeah, I can\ntry to speak to that.",
    "start": "4159680",
    "end": "4166441"
  },
  {
    "text": "AUDIENCE: The question\nI was going to ask is you can about\nthis theoretically. But I was going to ask, so\nif you had to start a company",
    "start": "4166441",
    "end": "4172210"
  },
  {
    "text": "right and you're relatively\nyoung in your career and this might be a\ncareer-ender in terms of if there's no success, what\nincentives would incentivize",
    "start": "4172210",
    "end": "4179140"
  },
  {
    "text": "you to start a company or solve\nthis problem or an organization to work on this exactly?",
    "start": "4179140",
    "end": "4184540"
  },
  {
    "text": "AUDIENCE: Presuming you have\nthe equipment and resources. AUDIENCE: So antibiotics are\npretty difficult, first of all,",
    "start": "4184540",
    "end": "4191469"
  },
  {
    "text": "because they're becoming too\neffective for their own good. I think it was Pfizer or\none of the big companies",
    "start": "4191470",
    "end": "4197890"
  },
  {
    "text": "produce a very famous\nkind of antibiotic drug. And now, it's just so effective\nthat they've kind of become",
    "start": "4197890",
    "end": "4206080"
  },
  {
    "text": "a victim of their own success. And also, it's also really\nhard to pass antibiotic drugs",
    "start": "4206080",
    "end": "4211119"
  },
  {
    "text": "through clinical trials,\ndisproportionately so compared to other diseases. So that's also kind of\nlike a barrier to entry.",
    "start": "4211120",
    "end": "4219310"
  },
  {
    "text": "I think, honestly, if I were\nto want to get into this field,",
    "start": "4219310",
    "end": "4224470"
  },
  {
    "text": "you have to come up\nwith a new approach, something better than\nis being done right now.",
    "start": "4224470",
    "end": "4229650"
  },
  {
    "text": "Because I think antibiotics\nit's a very broad field.",
    "start": "4229650",
    "end": "4235440"
  },
  {
    "text": "There's so many\ndifferent strains. And if they mutate\na bit your drug can be already\nrendered ineffective.",
    "start": "4235440",
    "end": "4241679"
  },
  {
    "text": "So it's just one of those\nfields that is always evolving. So not only do you have to\nhave very strong basic science",
    "start": "4241680",
    "end": "4247875"
  },
  {
    "text": "to keep up with what's\nhappening with these bacteria, how are they like mutating, and\nhow are they kind of evolving,",
    "start": "4247875",
    "end": "4255090"
  },
  {
    "text": "and then you have to come up\nwith drugs to help target them. So it's like a very\ntwofold problem",
    "start": "4255090",
    "end": "4260340"
  },
  {
    "text": "that you need to\nsimultaneously target. And then obviously,\nthey're evolving so rapidly that you have to\nkind of pivot very quickly.",
    "start": "4260340",
    "end": "4269250"
  },
  {
    "text": "So I think it's one of those\nfast-changing fields that is kind of hard to target.",
    "start": "4269250",
    "end": "4274829"
  },
  {
    "text": "But definitely important. I'm not really sure\nwhat mechanisms they have in place\nor organization-wise",
    "start": "4274830",
    "end": "4282120"
  },
  {
    "text": "to kind of target\nthis specifically. But I think it definitely\nshould be a focus. AUDIENCE: You talked about\nyour pipeline getting approved.",
    "start": "4282120",
    "end": "4292110"
  },
  {
    "text": "What if they could speed\nthat up very quickly so it's a priority? AUDIENCE: I mean,\nspeeding it up would help.",
    "start": "4292110",
    "end": "4297930"
  },
  {
    "text": "But also, it's just hard to\nproduce a good clinical trial",
    "start": "4297930",
    "end": "4303020"
  },
  {
    "text": "for these drugs. So I think that's also\na fundamental problem. It's just like\npsychiatric drugs. Those are very notoriously\nhard to prove because placebo",
    "start": "4303020",
    "end": "4311160"
  },
  {
    "text": "effect is really a big problem. WILLIAM BONVILLIAN:\nSo that leads us right into our\nnext reading, which",
    "start": "4311160",
    "end": "4318659"
  },
  {
    "text": "is this FDA problem and the fact\nthat we haven't put resources on the drug approval process.",
    "start": "4318660",
    "end": "4325800"
  },
  {
    "text": "So Chloe, it's yours. AUDIENCE: So if\nwe're starting off",
    "start": "4325800",
    "end": "4331880"
  },
  {
    "text": "with tackling that problem\nof how do we sort of reform and revamp the way in which\nwe evaluate these products,",
    "start": "4331880",
    "end": "4339900"
  },
  {
    "text": "one question for\nyou guys would be-- so the meeting\nmentioned that one",
    "start": "4339900",
    "end": "4345570"
  },
  {
    "text": "of the things you could\nattribute this mismatch was a mismatch between the\nlevels of how far both research",
    "start": "4345570",
    "end": "4352710"
  },
  {
    "text": "in basic science and applied\nscience, where they put that. They're very mismatched\nin terms of one of them is just shot ahead and\nthe other can't even keep up.",
    "start": "4352710",
    "end": "4359760"
  },
  {
    "text": "So what are your thoughts on how\nor if an agency such as the FDA",
    "start": "4359760",
    "end": "4366173"
  },
  {
    "text": "should be responsible\nfor ensuring the development of these\nsciences are evenly matched? For example, should\nthe agency bottleneck",
    "start": "4366173",
    "end": "4373560"
  },
  {
    "text": "the funding for basic sciences\nuntil applied sciences and catch up? Or should they aggressively\nstimulate opportunities",
    "start": "4373560",
    "end": "4379620"
  },
  {
    "text": "on other side? AUDIENCE: I suppose\nin an ideal scenario you just stimulate that's more\nfunding to research drugs.",
    "start": "4379620",
    "end": "4388200"
  },
  {
    "text": "But I understand that there\nisn't always money for that. AUDIENCE: I forget--\nbut to that point,",
    "start": "4388200",
    "end": "4394038"
  },
  {
    "text": "there is another reading. I forget if it was\nthis one or not. But it said, just throwing money\nand giving infinite budgets",
    "start": "4394038",
    "end": "4400110"
  },
  {
    "text": "isn't always the solution\nbecause, in that case, it takes away the\nelement of good planning",
    "start": "4400110",
    "end": "4407489"
  },
  {
    "text": "and strategic planning. WILLIAM BONVILLIAN: The end\nof innovation organization. If you don't have the\ninnovation organization,",
    "start": "4407490",
    "end": "4413347"
  },
  {
    "text": "that's going to enable you to\navoid big gaps in the system. You're just not\ngoing to get there. So throwing money at a problem\nwithout tackling the innovation",
    "start": "4413347",
    "end": "4421440"
  },
  {
    "text": "organization problems\nis problematic. AUDIENCE: Ideally, yes.",
    "start": "4421440",
    "end": "4427572"
  },
  {
    "text": "Money in, money would-- AUDIENCE: Yeah, assuming that\nyou can use the money properly. Yeah. ",
    "start": "4427572",
    "end": "4435675"
  },
  {
    "text": "AUDIENCE: One thing that\nI was curious about. I was confused how\nantibiotics can simultaneously be working too well\nand you can have",
    "start": "4435675",
    "end": "4442620"
  },
  {
    "text": "tons of antibiotic-resistant\nbacteria, which implies that antibiotics\nare not working too well.",
    "start": "4442620",
    "end": "4448230"
  },
  {
    "text": "So if someone could clarify\nthat, I would appreciate that. WILLIAM BONVILLIAN:\nThat's yours, Chris.",
    "start": "4448230",
    "end": "4453770"
  },
  {
    "text": "AUDIENCE: So I think the problem\nis that, say, Pfizer's drug is doing really well.",
    "start": "4453770",
    "end": "4459660"
  },
  {
    "text": "So they give these\nantibiotics to their patients. And these patients\nare getting cured.",
    "start": "4459660",
    "end": "4466200"
  },
  {
    "text": "And so that means, if\nthey're getting cured and they're not really\ngetting these diseases, that means that\ndrug is not going",
    "start": "4466200",
    "end": "4472790"
  },
  {
    "text": "to be really used as much. And then at the same time,\nbecause these patients have used the drug, there is\nantibiotic resistance growing.",
    "start": "4472790",
    "end": "4481580"
  },
  {
    "text": "And just because it's\nbeen around for so long, it's inevitable\nthat resistance is",
    "start": "4481580",
    "end": "4487752"
  },
  {
    "text": "going to build up to the\npoint that the drug is no longer effective. Because it's been\nout for 10, 15 years.",
    "start": "4487752",
    "end": "4495177"
  },
  {
    "text": "AUDIENCE: But that\nresistance can only develop if lots of people\nare using the drug-- AUDIENCE: I mean, obviously,\na lot of people have used it.",
    "start": "4495177",
    "end": "4501467"
  },
  {
    "text": "And it is, obviously, a\ncritical mass have used it. It's been successful. ",
    "start": "4501467",
    "end": "4507619"
  },
  {
    "text": "It's a really effective drug. So maybe there's not\nrepeat people in the way",
    "start": "4507620",
    "end": "4514550"
  },
  {
    "text": "that other drugs might\nhave a lot of repeat users. Maybe it's treating\na large population,",
    "start": "4514550",
    "end": "4519560"
  },
  {
    "text": "but people don't really\nget the same kind of strain of disease multiple\ntimes, something like that.",
    "start": "4519560",
    "end": "4525500"
  },
  {
    "text": "WILLIAM BONVILLIAN: And\nChris, part of the problem is that we overprescribe\nantibiotics to an absurd extent.",
    "start": "4525500",
    "end": "4530720"
  },
  {
    "text": "And we're sticking antibiotics\nin everything like hand soap. And we're virtually guaranteeing\nour own Darwinian dilemma.",
    "start": "4530720",
    "end": "4539600"
  },
  {
    "text": "AUDIENCE: It seems\nto be applying the language of this class\nin previous lectures.",
    "start": "4539600",
    "end": "4544620"
  },
  {
    "text": "We're playing catch-up with\nan innovation problem instead of purely innovating,\nwhich doesn't",
    "start": "4544620",
    "end": "4550349"
  },
  {
    "text": "seem like a very American\nway to tackle this problem. It's kind of odd\nbecause it's almost",
    "start": "4550350",
    "end": "4556230"
  },
  {
    "text": "like we're being outplayed\nby nature, which, I mean, most of our big successes\nover the last 200 or 300 years",
    "start": "4556230",
    "end": "4561767"
  },
  {
    "text": "have been us figuring out\nhow to manipulate nature to our advantage. So it's kind of an\ninteresting [INAUDIBLE]..",
    "start": "4561767",
    "end": "4567666"
  },
  {
    "text": "AUDIENCE: I left my\nAmerican flag at home.  AUDIENCE: If that's\nall we have for that,",
    "start": "4567666",
    "end": "4574110"
  },
  {
    "text": "I do have one more question\nfor the FDA reading, more on the standard setting\nsorts of things things.",
    "start": "4574110",
    "end": "4581590"
  },
  {
    "text": "What do you guys think,\nagain, are the roles and responsibilities\nof such an agency that",
    "start": "4581590",
    "end": "4588180"
  },
  {
    "text": "sets these standards\nto encourage people to take risks and\nbring the slightly",
    "start": "4588180",
    "end": "4593770"
  },
  {
    "text": "riskier drugs to market? Because the reading mentioned\nthat a lot of researchers won't even go down that\npath because they know how",
    "start": "4593770",
    "end": "4599503"
  },
  {
    "text": "arduous and tough [INAUDIBLE]. So is there something\nthe FDA could do to--",
    "start": "4599503",
    "end": "4605878"
  },
  {
    "text": "AUDIENCE: I like what Bill\nsaid in terms of like, OK, it's a very hard process. But once you do it,\nyou're kind of set.",
    "start": "4605878",
    "end": "4611325"
  },
  {
    "text": "The only thing I would\nquestion is I would tier it. Because there's probably\ndifferent kinds of drugs that have different specialties.",
    "start": "4611325",
    "end": "4617233"
  },
  {
    "text": "And they're probably\nsomething that-- there's pretty\ndrugs that I really want to get tested\nreally, really well. Or there's some that,\neven if I do test them,",
    "start": "4617233",
    "end": "4623910"
  },
  {
    "text": "I still don't know and some\ndrugs that can probably get passed faster. So I would figure out like\nhow does this scheme work.",
    "start": "4623910",
    "end": "4631560"
  },
  {
    "text": "Look at the data in terms of how\nare these drugs being passed, how long does it take, which\nones were relatively quick",
    "start": "4631560",
    "end": "4637200"
  },
  {
    "text": "and see if I could restructure\nthe organization so that I can optimize for the\nstuff that really matters",
    "start": "4637200",
    "end": "4642920"
  },
  {
    "text": "and the stuff that doesn't\nreally matter as much, it's not a focus. So we're having a linear kind\nof everything is the same.",
    "start": "4642920",
    "end": "4650580"
  },
  {
    "text": "AUDIENCE: So are you saying\nmaybe make the funding or whatever a function of, say,\nquality and the amount of time",
    "start": "4650580",
    "end": "4657090"
  },
  {
    "text": "it would take to get passed so\nthen, if you need a drug that maybe would only work for a\nfew people, you can make it",
    "start": "4657090",
    "end": "4663840"
  },
  {
    "text": "so it would be\nreally high quality. Whereas if you have\na drug that needs to work for a lot of people\nthat you need really quickly,",
    "start": "4663840",
    "end": "4669180"
  },
  {
    "text": "then you can make\nit so that it's less robust or for fewer\nrestraints, et cetera,",
    "start": "4669180",
    "end": "4674440"
  },
  {
    "text": "embracing something like that? AUDIENCE: Yeah,\nsomething like that. Because you also think\nabout compound interest.",
    "start": "4674440",
    "end": "4679690"
  },
  {
    "text": "So say I know that,\nif I make this drug, I'm going to save the government\nlike $50 million a year or $80 million a year\nover four or five years.",
    "start": "4679690",
    "end": "4687828"
  },
  {
    "text": "So if it's something that's\ngoing to make a big impact, how about we go faster\nand we can iterate faster? So we have priorities for drugs\nthat really, really matter.",
    "start": "4687828",
    "end": "4695030"
  },
  {
    "text": "I don't like the argument of\nsaying, oh, not a lot of people are going to use it so we're\nnot going to prioritize it. And let's put it in the back\nbecause it's kind of false.",
    "start": "4695030",
    "end": "4701980"
  },
  {
    "text": "Or maybe you should create\nanother organization that only focuses on\nthose kinds of drugs and split up the FDA\ninto one that focuses on",
    "start": "4701980",
    "end": "4708360"
  },
  {
    "text": "that so it gets equal review. But that's kind of\na same wavelength.",
    "start": "4708360",
    "end": "4713760"
  },
  {
    "text": "WILLIAM BONVILLIAN: So\njust to kind of summarize here from your all good\npresentations and good",
    "start": "4713760",
    "end": "4720870"
  },
  {
    "text": "questions, the FDA is sitting\non a really critical part",
    "start": "4720870",
    "end": "4726620"
  },
  {
    "text": "of the problem. So if we could significantly\nspeed the drug approval process",
    "start": "4726620",
    "end": "4732199"
  },
  {
    "text": "and if we could\nsignificantly lower its cost, we solve a lot of problems here.",
    "start": "4732200",
    "end": "4738300"
  },
  {
    "text": "We can be much less reliant\non a blockbuster drug model. So it seems to me that, in\nterms of the panoply of fixes",
    "start": "4738300",
    "end": "4745340"
  },
  {
    "text": "to this gap in the\ninnovation system, really paying attention\nto how to accelerate--",
    "start": "4745340",
    "end": "4752020"
  },
  {
    "text": "Martine, as you\nwere pointing out-- the review process at FDA. And it's very hard to\nreduce safety requirements.",
    "start": "4752020",
    "end": "4763090"
  },
  {
    "text": "It's just not going to be\nacceptable to the public. But if there are new ways of\nusing big data and analytics",
    "start": "4763090",
    "end": "4770100"
  },
  {
    "text": "and simulation and\nmodeling, those potentially present very significant\nimprovements to this process",
    "start": "4770100",
    "end": "4778680"
  },
  {
    "text": "here that could really\nhelp tackle this problem. So putting some money\non that one I think",
    "start": "4778680",
    "end": "4783870"
  },
  {
    "text": "could be really key. Then we go back\nto NIH, NIH is not organized around those kinds\nof technology problems.",
    "start": "4783870",
    "end": "4791870"
  },
  {
    "text": "So how are we going to do this? So we have another\ndilemma as soon as we arrive at the answer.",
    "start": "4791870",
    "end": "4797025"
  },
  {
    "text": "Anything else? ",
    "start": "4797025",
    "end": "4802640"
  },
  {
    "text": "AUDIENCE: I mean, just as we\ntransition into Bill's reading about this being a legacy sector\nor exhibiting a lot of legacy",
    "start": "4802640",
    "end": "4810580"
  },
  {
    "text": "features, I'm curious about\nwhat you, Bill, or the class thought about the\npolitical viability of,",
    "start": "4810580",
    "end": "4819290"
  },
  {
    "text": "I guess, in terms of\nMartine's proposal toward a tiered approach. If we thought it was more\npolitically viable to do this",
    "start": "4819290",
    "end": "4826090"
  },
  {
    "text": "for either therapeutic drugs\nor for cure-all interventions,",
    "start": "4826090",
    "end": "4831699"
  },
  {
    "text": "there seems, in my very limited\nstudy of the life sciences, to be a proclivity towards\nthe therapeutic drugs",
    "start": "4831700",
    "end": "4841000"
  },
  {
    "text": "and interventions\nbecause they're more sustainable and profitable. So do we think that that\ncould be a potential market",
    "start": "4841000",
    "end": "4848950"
  },
  {
    "text": "opportunity to test\na DARPA-like system or to test the sort of\nimproved speed of acceptance",
    "start": "4848950",
    "end": "4857980"
  },
  {
    "text": "of the drug? WILLIAM BONVILLIAN: Let me throw\nthat back to the group here. AUDIENCE: I like the point--",
    "start": "4857980",
    "end": "4863330"
  },
  {
    "text": "I forgot when we mentioned it\nabout how drugs were too low. So they want to have\nrecurring revenue.",
    "start": "4863330",
    "end": "4868810"
  },
  {
    "text": "But I think, as the\ngovernment, you get a lot of, you have to pay that. So it would be interesting\nif the government is like, OK, well, we\nknow, over the lifetime,",
    "start": "4868810",
    "end": "4875739"
  },
  {
    "text": "if we don't solve\nthis now, it's going to cost us one million\ndollars for this person. So you solve it\ntoday, we're going",
    "start": "4875740",
    "end": "4882420"
  },
  {
    "text": "to give you $20k, which\nis way cheaper for us overall in the long term. But you're not getting paid\n$10 per drug or $100 per drug.",
    "start": "4882420",
    "end": "4890360"
  },
  {
    "text": "And so it's kind of a\nwin-win because it's really good revenue for\nthe company and it justifies having a super drug\nthat really, really works.",
    "start": "4890360",
    "end": "4897760"
  },
  {
    "text": "And it gives them enough\nmoney on their balance sheet. I don't know if you guys know\nhow Warren Buffett got rich. But he got an insurance company.",
    "start": "4897760",
    "end": "4903610"
  },
  {
    "text": "And they give him a lot\nof cash so that they can invest in other companies. And it's really good for\ncompanies having a lot of cash",
    "start": "4903610",
    "end": "4909100"
  },
  {
    "text": "on hand. AUDIENCE: Who'd have thought? AUDIENCE: Well, no, it's\njust like a lot of them",
    "start": "4909100",
    "end": "4914680"
  },
  {
    "text": "don't have a lot of cash\non hand at any given time. So they have their assets\ndistributed between physical.",
    "start": "4914680",
    "end": "4920800"
  },
  {
    "text": "And so it's really good to be\nable to move quickly and buy all this stuff. And it's just not a thing\nthat happens that easily.",
    "start": "4920800",
    "end": "4926770"
  },
  {
    "text": "There's also a lot\nof tax benefits. That's why people do it. ",
    "start": "4926770",
    "end": "4940299"
  }
]